



Lady Reading Hospital Peshawar (MTI)

BID SOLICITATION DOCUMENTS

**Single Stage Two Envelope
Year 2024-2025**

A. MEDICAL DEVICES, SUTURE, COTTON & RELATED ITEMS

B. MEDICINES

C. NON-DRUG ITEMS

Note: The prospective bidder is expected to examine the Bidding Documents carefully, including all Instructions, Terms & Conditions, and Specifications etc. Failure to furnish all information required by the Bidding documents or submission of a Bid not substantially responsive to the Bidding Documents in every respect would result in the rejection of the Bid.

Assistant Manager Material Management
Director LRH/MTI Peshawar

Manager Pharmacy
LRH/MTI Peshawar

Associate Hospital
LRH/MTI Peshawar

Director Finance
LRH/MTI Peshawar

Nursing Director
LRH/MTI Peshawar

Medical Director
LRH/MTI Peshawar

Hospital Director
LRH/MTI Peshawar

| TABLE OF CONTENTS |
|--|
| Section I. Invitation for Bids |
| Section II. Bid Data Sheet |
| Section III. Special Conditions of Contract |
| Table of clauses |
| Section IV. Technical Specifications |
| Section V. Blacklisting and Debarment |
| Section VI. Schedule of Requirements |
| Section VII. Sample Forms |
| 1. Bid Cover sheet Form-1 |
| 2. Letter of Intention Bid Form- 2 |
| 3. Affidavit Form -3 |
| 4. Price Schedule Format Form -4 |
| 5. Integrity Pact Form-5 |
| 6. LRH-MTI Rate Contract Agreement Form-6 |

SECTION I. INVITATION FOR BIDS

Notes on the Invitation for Bids

The Invitation for Bids (IFB) has been issued as an advertisement in leading newspapers of general circulation in the Province of Khyber Pakhtunkhwa as well as on the web site of the LRH-MTI (<https://www.lrh.edu.pk/downloads/tenders.html>) by allowing at least fifteen days for NCB for bid preparation and submission.

The Invitation for Bids provides information that enables interested bidders to decide whether to participate. Apart from the essential items listed in the Standard Bidding Documents (SBD), the Invitation for Bids also indicates the important bid evaluation criteria or qualification requirement (for example, a requirement for a minimum level of experience in manufacturing a similar type of goods for which the Invitation for Bids is issued) so that the bidders should give their best and final prices as no negotiations are allowed.

The Invitation for Bids is incorporated into these Standard Bidding Documents (SBDs). The information contained in the Invitation for Bids (IFB) conforms to the bidding documents and in particular to the relevant information in the Bid Data Sheet.

LADY READING HOSPITAL PESHAWAR MEDICAL TEACHING INSTITUTE

TENDER NOTICE 2024-2025

(Single Stage–Two Envelopes)

(A) MEDICAL DEVICES, SUTURE, COTTON AND RELATED ITEMS; (B) MEDICINES; (C) NON-DRUG ITEMS FOR THE YEAR 2024-2025

1. In compliance with the Khyber Pakhtunkhwa Public Procurement Act-2012 and Khyber Pakhtunkhwa Procurement Regulatory Authority (KPPRA) Rules–2014, Lady Reading Hospital – Medical Teaching Institution, Peshawar invites sealed bids from

a. Manufacturer/s of

- A. Medical devices, suture, cotton and related items;
- B. Medicines;
- C. Non-drug items in Pakistan,

registered as such with the DRAP for the quoted item/s and regulated under the Drug Act 1976, DRAP Act 2012 and the Rules framed thereunder; and

b. Importer/s of

- A. Medical devices, suture, cotton and related items;
- B. Medicines;
- C. Non-drug items,

duly authorized by the goods' Principal Manufacturer or producer to import / supply the said goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed thereunder; and

2. The price shall be fixed and valid till **30th June 2025**.
3. Bidding competition under this advertisement shall be conducted through **Single Stage–Two Envelopes Bidding Procedure** as per KPPRA Act 2012 and Rules frame there under. Under this procedure, the bidders should submit the bids in two sealed envelopes of technical and financial bids, each of which must bear on them the clearly written words '**LRH-MTI Technical Bid 2024-2025**' and '**LRH-MTI Financial Bid 2024-2025**' as well as the full and complete identification of the bidder along with its postal and email addresses and phone number/s on each of the respective envelope. Both these sealed and labeled envelopes should bear the clearly written words '**Bid for LRH-MTI 2024-2025**' along with the identification and contact details of the bidder.
4. The Bid Solicitation Documents, of required items can be download from <https://www.lrh.edu.pk/downloads/tenders.html>
5. Bidders must submit sealed bids to the office of Hospital Director, located in the Administration Office within the premises of Lady Reading Hospital Medical Teaching Institution, Peshawar **on or before 14-05-2024 at 11:00 am**. Any bids presented / submitted / received later than this deadline, or delivered to some office other than the above office, shall not be considered and shall be rejected without any further processing.

6. Mandatory Bid Security / Earnest Money amounting to a flat rate of Rupees Five Hundred Thousand only (**Rs. 500,000/-**) from each bidder in the shape of Call Deposit Receipt (CDR) in the name of the **Hospital Director, Lady Reading Hospital – Medical Teaching Institutions** required to be submitted along with the Financial Bid within its sealed envelope. A separate photocopy of this Bids Security financial instrument should also be placed inside the sealed envelope of Technical Proposal. Ordinary crossed or open Cheque, PO (Pay order) shall not be acceptable as Bids security.
7. The pre bid will be held on **02-05-2024 at 11:00 hours** in the Material Management Department, LRH-MTI Peshawar.
8. Quotation must be computer typed & printed; and the offered rate must be written both in words & figures. An authorized person of the bidding entity shall sign & stamp all pages of the bid, as mentioned in the SBDs.
9. The bidders are required to submit the unit price of quoted items on the format as prescribed in the Standard Bidding Documents.
10. Quotations with cutting and over-writing shall not be accepted to the extent of that particular quoted item having cutting / over-writing / erasing etc.
11. To facilitate further data entry during bids processing, all bidders are also required to submit the quoted product list as per prescribed proformas in the approved Standard Bidding Documents for this bidding competition, in soft form (and not in other software formats or images) on USB, duly labeled by a permanent marker with the name of bidder firm along with the words “**LRH-MTI bid 2024-2025**”. The bidders must ensure that said USB is openable and readable. Moreover, in the same context, the bidders are also required to submit a table of contents in the start of bid with proper page numbering on each page of the bid.
12. Bids will be opened by the **Tender Opening Committee** of LRH-MTI at **14-05-2024 at 11:30 Am** in the Committee Room of Lady Reading Hospital, Medical Teaching Institution, Peshawar in the presence of those bidders or their representatives, who choose to attend the bids opening process.
13. The Purchase Committee reserves the right to reject any or all of the bids under clause 47 of KPPRA Procurement Rules 2014.

Associate Hospital Director
LRH-MTI Peshawar

Hospital Director
LRH-MTI Peshawar

Address of Bid Submission/Opening:
Lady Reading Hospital-MTI Peshawar,
Khyber Pakhtunkhwa.
Telephone(s): 0092-91-9211430

SECTION II. BID DATA SHEET

| ITB Ref. | Introduction/Description | Detail |
|---|---|---|
| ITB 1.1 | Name of Procuring/Procuring / purchasing entity of Government of Khyber Pakhtunkhwa. | Hospital Director, LRH-MTI, Peshawar, Khyber Pakhtunkhwa as the overall head of LRH-MTI, Peshawar, KP. |
| ITB 4.1 | Name of Procuring entity / purchasing entity. | Hospital Director, LRH-MTI, Peshawar, Khyber Pakhtunkhwa |
| ITB 6.1 | Procuring entity / purchasing entity's address, telephone, telex, and facsimile, numbers. | Hospital Director Lady Reading Hospital-MTI Khyber Pakhtunkhwa, Peshawar Tel No: 091-9211441-45 Fax No: 091- 9211401 Email: Info@lrh.gov.pk |
| ITB 8.1 | Language of the bid. | English |
| Bid Price and Currency | | |
| ITB 11.2 | Price quoted shall be: | Pakistani Rupees (Rs.) |
| ITB 11.5 | The price shall be fixed | The price shall be fixed and valid till 30 th June 2025 |
| Preparation and Submission of Bids | | |
| ITB 13.3 (d) | Qualification requirements. | Manufacturer of A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items in Pakistan, registered as such with the DRAP for the quoted item/s and regulated under the DRAP Act 2012 and the Rules framed thereunder; and Importer of A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items, duly authorized by the goods' Principal Manufacturer or producer to import / supply the said goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed thereunder; and |
| ITB 15.1 | Amount of bid security. | Rs.500,000/- |

| | | |
|-----------------------|---|---|
| ITB 16.1 | Bid validity period. | 180 days from the date of opening of bids |
| ITB 18.2 (a) | Address for bid submission. | Hospital Director Lady Reading Hospital-MTI Khyber Pakhtunkhwa, Peshawar Tel No: 091-9211441-45 Fax No: 091- 9211401 Email: Info@lrh.gov.pk |
| ITB 18.2 (b) | IFB title and number. | Selection and rate contracting of medical devices, surgical disposables & non-drug items for the year 2024-2025. |
| ITB 19.1 | Deadline for bid submission. | Mentioned in Advertisement |
| ITB 22.1 | Time, Date and Place for bid opening. | Mentioned in Advertisement |
| Bid Evaluation | | |
| ITB 25.3 | Criteria for bid evaluation. | Merit Point Evaluation (Highest Ranking Fair Bid). The items ranked highest in merit points (obtained through, and based on, technical and financial evaluation) will get unit rate central contract (Section-IV of these SBDs). |
| ITB 25.4 (h) | Details on the evaluation method or reference to the Technical Specifications | As in section on Technical Evaluation of bids. |
| Contract Award | | |
| ITB 29.1 | Percentage for quantity increase or decrease. | The Procuring/Procuring / purchasing entity in the capacity of being the overall head of the LRH-MTI, or otherwise has the authority to regulate, if deemed appropriate, under the provisions in ITB 29, through imposing restrictions and / or classifying and / or grouping any selected quoted item/s for stopping, increasing or decreasing the purchase of such item/s by the Procuring / purchasing entity/ices to rationalize and / or control the use and / or misuse of such item/s. |

SECTION III. SPECIAL CONDITIONS OF CONTRACT

Notes on the Special Conditions of Contract

Similar to the Bid Data Sheet in Section II, the clauses in this Section are intended to assist the Procuring entity / purchasing entity in providing contract-specific information in relation to corresponding clauses in the General Conditions of Contract.

The provisions of Section III complement the General Conditions of Contract included in Part one, Section II, specifying contractual requirements linked to the special circumstances of the Procuring entity / purchasing entity, the Procuring entity / purchasing entity's country, the sector, and the Goods purchased. In preparing Section III, the following aspects should be checked:

Information that complements provisions of Part one Section II must be incorporated.

Amendments and/or supplements to provisions of Part one Section II, as necessitated by the circumstances of the specific purchase, must also be incorporated.

As Per KPPRA rule 47. Rejection of bids. ---(1) The procuring entity may reject all bids or proposals at any time prior to the acceptance of a bid or proposal. The procuring entity shall upon request communicate to any contractor or consultant who submitted a bid or proposal, the grounds for rejection of all bids or proposals. (2) The procuring entity shall incur no liability, solely by virtue of its invoking subrule (1) towards contractors or consultants who have submitted bids or proposals. (3) Notice of the rejection of all bids or proposals shall be given promptly to all contractors or consultants that submitted bids or proposals.

Section III. Special Conditions of Contract

Table of Clauses

| | |
|-----|--|
| 1. | DEFINITIONS (GCC CLAUSE 1) |
| 2. | COUNTRY OF ORIGIN (GCC CLAUSE 3) |
| 3. | PERFORMANCE SECURITY (GCC CLAUSE 7) |
| 4. | INSPECTIONS AND TESTS (GCC CLAUSE 8) |
| 5. | PACKING (GCC CLAUSE 9) |
| 6. | DELIVERY AND DOCUMENTS (GCC CLAUSE 10) |
| 7. | INSURANCE (GCC CLAUSE 11) |
| 8. | INCIDENTAL SERVICES (GCC CLAUSE 13) |
| 9. | SPARE PARTS (GCC CLAUSE 14) |
| 10. | WARRANTY (GCC CLAUSE 15) |
| 11. | PAYMENT (GCC CLAUSE 16) |
| 12. | PRICES (GCC CLAUSE 17) |
| 13. | LIQUIDATED DAMAGES (GCC CLAUSE 23) |
| 14. | RESOLUTION OF DISPUTES (GCC CLAUSE 28) |
| 15. | GOVERNING LANGUAGE (GCC CLAUSE 29) |
| 16. | APPLICABLE LAW (GCC CLAUSE 30) |
| 17. | NOTICES (GCC CLAUSE 31) |
| 18. | DUTIES AND TAXES (GCC CLAUSE-35) |

Special Conditions of Contract

The following Special Conditions of Contract shall supplement the General Conditions of Contract (GCC). Whenever there is a conflict, the provisions herein shall prevail over those in the General Conditions of Contract. The corresponding clause number of the GCC is indicated in parentheses.

Definitions (GCC Clause 1)

GCC 1.1 (c) The Goods are: A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items

GCC 1.1 (g) The Procuring entity / purchasing entity is: Hospital Director being the overall head of Lady Reading Hospital – Medical Teaching Institute; and

The Procuring / purchasing entity/ices include: Hospital Director being the overall head of Lady Reading Hospital – Medical Teaching Institute;

GCC 1.1 (i) The Supplier is: “the individual or firm supplying the Goods and Services under this Contract” and includes the following:

Manufacturer of A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items in Pakistan, registered as such with the DRAP for the quoted item/s and regulated under the DRAP Act 2012 and the Rules framed thereunder; and

Importer of A) Medical devices, suture, cotton and related items; (B) Medicines;

(C) Non-drug items, duly authorized by the goods’ Principal Manufacturer or producer to import / supply the said goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed thereunder; and

Sample Provision:

GCC 1.1 (j)—The Project Site is: Office of Hospital Director being the overall head of Lady Reading Hospital – Medical Teaching Institute Peshawar

GCC 8.1: When required, the Focal Person of the bidder will be informed on phone or through email to provide samples of the items in sufficient / required quantity for examination / analysis /expert opinion to the office of Manager Pharmacy at bidder's own risk and cost at, and not later than, the time and date communicated. The samples will be non-returnable and no payment whatsoever shall be payable to bidder / Focal Person on this account in the name of price/transportation charges etc. or on the basis of any other context or reason or argument.

Country of Origin (GCC Clause 3)

All countries and territories as indicated in the bidding documents, “Eligibility for the Provisions of Goods, Works, and Services in Government-Financed Procurement”.

Performance Security (GCC Clause-7)

GCC 7.1—the amount of performance security, as a percentage of the Contract Price, shall Not be required. However, the bid security of 500,000/-from the successful bidders as received at the time of bids submission, shall be retained by the Procuring/Procuring / purchasing entity as Performance Security till the end of contract period and will be released back to successful bidders after the expiry of contract period, subject to the condition that all contractual obligations related to supplies are fulfilled. However, the warranty of the supplied goods, as issued by the Supplier under the clauses of contract agreement (Bid Form-6) and relevant applicable laws governing the nature of goods, e.g., the Drug Act 1976, shall remain in force and valid despite the discharge of Performance Security to the Supplier in accordance with GCC Clause-7 and 8.

Standards (GCC Clause 4):

Inspections and Tests (in accordance with the clauses of contract with the Procuring entity / purchasing

entity)

The Technical Evaluation shall be conducted by the Inspection Team/s of LRH-MTI expert/s constituted by the Hospital Director LRH MTI to:

undertake examination of the mandatory documents as mentioned in the Bid Cover Sheet (Bid Form-1) of these SBDs, and the attested copies of which had been submitted by the bidder/s along with the technical bids; and

A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items shall be examined and / or tested by LRH MTI expert/s of the T&E Committee in a manner as deemed relevant and appropriate for the purpose by the said expert/s, and as laid down, or otherwise, in the applicable laws and Rules, for submission of technical report to the relevant forum/quarter for the needful.

The DTL report of the quoted Medicines and Surgical Disposables not older than one year be examined.

To fulfill the relevant clauses of the contract agreement (Bid Form-6 of these SBDs) for testing of supplied goods, all the successful bidders for Surgical Disposables and Medical Devices falling under the Drugs Act 1976, before signing the Contract Agreement (Bid Form-6) shall provide to the Procuring entity / purchasing entity, the Testing Method/s and Lab. protocols to test their quoted item/s in the Drugs Testing Laboratory.

Any other appropriate method/arrangements may be adopted by the T&E Committee to assess and/or assure the quality of goods being purchased and / or supplied to the Procuring and / or procuring / purchasing entity/ices.

Packing (GCC Clause 9)

The successful bidder shall make supplies of quoted item/s in accordance with the following:

Provisions contained in the GCC Clause 9 of these SBDs; and

Relevant clauses of contract agreement of LRH-MTI with the Supplier/s (Section- VI of these SBDs –Rate Contract Agreement); and

Delivery and Documents (GCC Clause 10)

Applicable Delivery Mode: Delivered Duty Paid (DDP) as per contract agreement of the successful bidder with the Procuring entity / purchasing entity.

The Supplier shall provide the following documents to the Procuring / purchasing entity:

copies of the Supplier's invoice showing goods' description, quantity, unit price, and total amount;

Usual transport documents which the buyer may require to take the goods;

Manufacturer / Importer's prescribed warranty certificate;

The supplier shall be responsible to transport the item/s in a manner that the appropriate and required storage temperature is continuously and properly maintained during transportation from supplier till delivery to the Procuring / purchasing entity/ices. In case of item/s requiring the maintenance of cold chain, the supplier shall be under obligation to provide valid and appropriate evidence to the Procuring / purchasing entity to the effect that end-to-end cold chain of the supplied item/s has adequately been maintained during transportation of the said item/s to the Procuring / purchasing entity/ices.

Insurance (GCC Clause 11)

GCC 11.1— The Goods supplied under the Contract shall be delivered duty paid (DDP) under which risk

Insurance (GCC Clause 11)

GCC 11.1— The Goods supplied under the Contract shall be delivered duty paid (DDP) under which risk is transferred to the buyer after having been delivered, hence insurance coverage is sellers' responsibility. Since the Insurance is seller's responsibility, they may arrange appropriate coverage.

Warranty (GCC Clause 15)

For goods belonging to the categories of Medical Devices, Surgical Disposables, medicine and Cotton

related materials, and falling under the Drugs Act 1976 and / or the DRAP Act-2012 and Rules framed thereunder, the Supplier, in addition to the terms and conditions of the Rate Contract Agreement with Procuring entity / purchasing entity (Bid Form-6), shall provide warranty to the Procuring / purchasing entity under all the relevant Section/s of applicable government laws and rules.

In case of goods belonging to the categories of NDIs, the Supplier as per GCC Clause 15 and the clauses of Contract Agreement with the Procuring entity / purchasing entity (Bid Form-6) shall provide warranty to the Procuring / purchasing entity for the duration as mentioned in GCC Clause-15 or till the expiry date of goods supplied, whichever is later.

Payment (GCC Clause 16):

GCC Clause 16 as well as under the terms and condition in Rate Contract Agreement with the Procuring entity / purchasing entity.

Payment shall be made in **Pak. Rupees** in accordance with the relevant government rules, regulations and procedures.

Prices (GCC Clause 17)

The bidder shall not quote price/s of any item/s which is/are higher than the prices quoted by the bidder across the country to any entity procuring the quoted item/s through public funding.

In case of medical devices, surgical disposables and non-drug items, the bidder shall quote the lowest minimum price of individual quoted item/s.

In case of Medical Devices, Surgical Disposables and NDIs, the bidder shall not quote the prices more than the prevailing market trade price of the quoted item/s for bulk purchases.

Liquidated Damages (GCC Clause 23)

As in relevant clauses of the Rate Contract Agreement signed by the Supplier with the Procuring entity / purchasing entity.

Disputes Resolution (GCC Clause 28)

The dispute resolution mechanism to be applied will be pursuant to relevant clauses of Rate Contract Agreement (Bid Form-6) between the Supplier and the Procuring entity / purchasing entity.

If at all required, the jurisdiction of Court shall be of Peshawar, Khyber Pakhtunkhwa.

Governing Language (GCC Clause 29)

The Governing Language shall be: **English.**

Applicable Law (GCC Clause 30)

The Contract shall be interpreted in accordance with all the relevant laws of Islamic Republic of Pakistan which include, but not limited to, the following legislations:

The KPPRA Act 2012

The KPPRA Rules 2014

The Drugs Act 1976 and Rules framed thereunder

The DRAP Act 2012 and Rules framed thereunder

The General Financial Rules of the Government of Khyber Pakhtunkhwa and all the relevant laws, rules and regulations pertaining to budgeting and financial management of public funds.

The Employment of Children (ECA) Act 1991

The Bonded Labor System (Abolition) Act of 1992

The Factories Act 1934

Notices (GCC Clause 31)

GCC 31.1—procuring entity / purchasing entity address for notice purposes:

Office of the Hospital Director

Lady Reading Hospital (MTI), Peshawar,
Khyber Pakhtunkhwa, Pakistan

Tel: 091-9211441-45,
Fax: 091-9211401,
Email: **info@lrh.gov.pk**

Supplier's address for notice purposes: As mentioned in their bidding documents

Duties & Taxes (GCC clause 32)

The Unit price quoted by the bidder shall be: **inclusive** of all applicable duties and taxes.

SECTION IV. TECHNICAL SPECIFICATIONS

Technical Evaluation Criteria for Medical Devices, Sutures, Cotton, related products, Biologicals, Medicine, Surgical, Disposable and Non-Drug Items

(Maximum Allocable Marks Score for Technical Evaluation = 70 Marks)

NOTE For further details of evaluation criteria and marking scheme, please see relevant proformas for technical evaluation these BSDs.

SYSTEM BREAKING / DISQUALIFICATION POINTS INTECHNICAL EVALUATION CRITERIA:

These system breaking / disqualification points mentioned in this section are in addition to the provision of mandatory documents, as elaborated in Bid Cover Sheet (Bid Form-1).

During technical evaluation of the quoted bids, bidders may stand disqualified if the Scrutiny Committee for bids evaluation find and declare any of the shortcoming/s related to the documents and/or manufacturing units and / or the Importers regardless of completion / fulfillment or otherwise of any terms and conditions, criteria and /or codal formalities.

In those cases, where sample evaluation is included in the technical criteria, rejection of the quoted items by the LRH expert committee for Physical evaluation of samples will lead to disqualification.

Financial Evaluation and Scoring System for Bids

(Maximum Allocable Marks Score = 30 marks)

The financial bids of technically qualified bidders will be opened publicly at the time to be announced by the Procuring entity / purchasing entity and the financial bids found technically non-responsive shall be returned un-opened to the respective Bidders.

Total Allocable marks for Technical Proposal = 70,

Passing technical Marks: 49

Total Allocable marks in Financial Proposal= 30

Total Combined Allocable Score for individual bids =Marks obtained in Technical Evaluation + Marks obtained in Financial Evaluation = 100

Scoring Methodology:

Contract will be awarded to the lowest evaluated responsive firm whose product ranks highest in the Combined Evaluation scoring calculated through the Marks awarded to Technical Proposal and Financial Proposal as stated in the Bid Data Sheet of these BSD's

The Evaluation Methodology is a combination of non-price factors (in Technical Criteria) and price factor (in Financial Criteria); and each having points as elaborated in the evaluation proforma as provided in these SBDs.

As evident from allocable score above and because of the importance and complexities/sensitivities in the field of procurement and use of Drugs and other products related to human lives and health, this Methodology puts greater emphasis on non-price factors like high quality of the product derived from excellent-grade raw material, stringent product certifications, international best pharmaceutical quality control practices in laboratories, Pharmaco-vigilance systems for Drug safety reporting and monitoring; and the most efficient industrial processes in the manufacturing premises.

Procedure for the Marks Scoring: Marks will be awarded or otherwise for various technical parameters to each quoted product based on the prescribed Technical and Financial criteria. The total combined marks will determine the highest-ranking product in each product category for contract award.

The formula to calculate the marks for the price by the bidders other than lowest bidder is given below:

Financial Evaluation Score of individual quoted Product:

= [Lowest quoted Price of the item ÷ Next higher proposed Price of the competing item] x Total allocable financial score

Solved Example of Financial Scoring:

If the lowest quoted price of an item is Rs. 86/-, the same lowest bidder will obtain score as below:

= $[86 \div 86] \times 30$

= 50 marks, being the lowest bidder for the quoted item.

If the next higher quoted price of the same item is Rs. 105/-, the marks obtained will be:

= $[86 \div 105] \times 30 = 24.57$ Marks

If the next higher quoted price of the same item is Rs. 130/-, the marks obtained will be:

= $[86 \div 130] \times 30 = 19.85$ Marks

.... And so on.

| A-1. Evaluation Criteria for Manufacturers of MEDICAL DEVICES, SUTURES, COTTON AND RELEVANT GOODS for LRH-MTI Peshawar 2024-2025 | | | |
|--|--|-------|---------|
| Firm / Company Name: | | | |
| S.No. | Parameters | Marks | Remarks |
| TECHNICAL EVALUATION | | | |
| 1 | Current export certificate of the quoted products from DRAP not older than TWO years (certificate duly attested by senior executive of the firm). | 4 | |
| 2 | Valid ISO 14001 certificate issued by PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 2 | |
| 3 | Valid ISO 9001 certificate issued by PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 2 | |
| 4 | Valid ISO 10993 certificate issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin <i>(To be verified by technical evaluation committee).</i> | 2 | |
| 4 | Valid ISO 13485 certificate equivalent document issued by PNAC accredited / equivalent body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 5 | Certificate of Adherence to Good storage practices (GSP) duly verified by DRAP/Authorized body for finished goods storage of the quoted item/s. | 5 | |
| 6 | Certificate of Functional HVAC / Air conditioning and ventilation system (certificate duly attested by senior executive of the firm and verified by DRAP/Authorized body). | 5 | |
| 7 | Adequate number of qualified persons (Certified by the senior executive of the firm) | 5 | |
| 8 | Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than ONE year (Certificate duly attested by the senior executive of the firm) | 5 | |
| 10 | Certificate of Analysis of finished quoted item/s from the Principal Manufacturer, duly attested by the senior executive of the firm | 5 | |
| 11 | Physical examination of the quoted item/s by the LRH-MTI expert committee. (Excellent=15, Good=7, satisfactory=3); <i>non-recommendation shall lead to disqualification</i> | 15 | |
| 12 | Valid Calibration certificate of the equipment in the factory (certificate duly attested by senior executive of the firm) | 5 | |
| 13 | Last Year performance of the firm – 02 marks for each performance certificate issued by relevant authority of the hospital with a capacity of 250 beds or above <i>(To be verified by technical evaluation committee).</i> | 10 | |
| FINANCIAL EVALUATION | | | |
| 14 | Quoted unit Price | 30 | |
| 15 | Lowest Quoted Unit Price among the qualified bids for particular item | | |
| 16 | Maximum Allocable Unit Price Score | | |
| 17 | Score awarded to the unit price of quoted item | | |
| TOTAL MARKS | | 100 | |

| A-2. Evaluation Criteria for Importers OF MEDICAL DEVICES, SUTURES, COTTON AND RELEVANT GOODS for LRH-MTI Peshawar 2024-2025 | | | |
|--|---|-------|---------|
| Firm / Company Name: | | | |
| S.No. | Parameters | Marks | Remarks |
| TECHNICAL EVALUATION | | | |
| 1 | Valid ISO 14001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 2 | Valid ISO 9001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 3 | Valid ISO 13485 certificate equivalent document issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 4 | Valid ISO 10993 certificate issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 5 | Certificate of Adherence to Good storage practices (GSP) duly verified by DRAP/Authorized body for finished goods storage of the quoted item/s. (Certificate duly attested by senior executive of the firm in Pakistan). | 5 | |
| 6 | Adequate number of qualified persons (Certified by the senior executive of the firm in Pakistan) | 5 | |
| 7 | Good Declaration certificate of imported finished item/s by the firm from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than ONE year (Certificate duly attested by the senior executive of the firm) | 5 | |
| 8 | Certificate of Analysis of finished quoted item/s from the Principal Manufacturer, duly attested by the senior executive of the firm | 5 | |
| 9 | Physical examination of the quoted item/s by the LRH-MTI expert committee. (Excellent=15, Good=7, satisfactory=3); non-recommendation shall lead to disqualification. | 15 | |
| 12 | Valid Calibration certificate of the equipment in the factory (certificate duly attested by senior executive of the firm) | 5 | |
| 13 | Last Year performance of the firm – 02 marks for each performance certificate issued by relevant authority of the hospital with a capacity of 250 beds or above <i>(To be verified by technical evaluation committee).</i> | 10 | |
| FINANCIAL EVALUATION | | | |
| 12 | Quoted unit Price | 30 | |
| 13 | Lowest Quoted Unit Price among the qualified bids for particular item | | |
| 14 | Maximum Allocable Unit Price Score | | |
| 15 | Score awarded to the unit price of quoted item | | |
| TOTAL MARKS | | 100 | |

| B-1. Evaluation Criteria for Manufacturers of MEDICINE for LRH-MTI Peshawar 2024-2025 | | | |
|---|--|-------|---------|
| Firm / Company Name: | | | |
| S.No. | Parameters | Marks | Remarks |
| TECHNICAL EVALUATION | | | |
| 1 | API source by WHO, US-FDA, EMA, MHRA, TGA, PDMA, Swiss Medics in health Canada or by other members/associates of SRA, to be compared with Goods declaration [10 marks]. Other than the above countries [5 marks]. | 10 | |
| 2 | Valid ISO 14001 certificate issued by PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 3 | Valid ISO 9001 certificate issued by PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 4 | Valid ISO 18001/45001 certificate issued by PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 5 | Current Export certificate of the quoted items from DRAP not older than TWO years (certificate duly attested by senior executive of the firm). | 5 | |
| 6 | Valid Calibration Certificate for equipment in the manufacturing unit (certificate duly attested by senior executive of the firm). | 5 | |
| 7 | Certificate of Adherence to Good Storage practices (GSP) duly verified by DRAP/Authorized body for finished Goods and storage of quoted items (certificate duly attested by senior executive of the firm). | 3 | |
| 8 | Adequate number of qualified persons and relevant Human resource (Certified duly attested by the senior executive of the firm) | 2 | |
| 9 | Certificate of Functional HVAC / Air conditioning and ventilation system (certificate duly attested by senior executive of the firm and verified by DRAP/Authorized body). | 5 | |
| 10 | Goods Declaration certificate of imported APIs of quoted items from Pakistan Customs (Certificate duly attested by the senior executive of the firm) | 5 | |
| 11 | Certificate of analysis of quoted items from the principal manufacturer (duly attested by senior executive of the firm). | 5 | |
| 12 | Availability of quoted items in Pakistani Market as per recent most data of IQVIA/ IMS Data (1-20% shares= 2 mark , 21-40%= 3 marks , 41% and above= 5marks) | 5 | |
| 13 | Last Year performance of the firm – 02 marks for each performance certificate issued by relevant authority of the hospital with a capacity of 250 beds or above <i>(To be verified by technical evaluation committee).</i> | 10 | |
| FINANCIAL EVALUATION | | | |
| 14 | Quoted unit Price | 30 | |
| 15 | Lowest Quoted Unit Price among the qualified bids for particular item | | |
| 16 | Maximum Allocable Unit Price Score | | |
| 17 | Score awarded to the unit price of quoted item | | |
| TOTAL MARKS | | 100 | |

B-2. Evaluation Criteria for Importer of MEDICINE for LRH-MTI Peshawar 2024-2025

Firm / Company Name:

| S.No. | Parameters | Marks | Remarks |
|-----------------------------|---|-------|---------|
| TECHNICAL EVALUATION | | | |
| 1 | API source by WHO, US-FDA, EMA, MHRA, TGA, PDMA, Swiss Medics in health Canada or by other members/associates of SRA, to be compared with Goods declaration [10 marks]. Other than the above countries [5 marks]. | 10 | |
| 2 | Valid ISO 14001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 3 | Valid ISO 9001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 4 | Valid ISO 18001/45001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 5 | Certificate of Adherence to Good Storage practices (GSP) duly verified by DRAP/Authorized body for finished Goods and storage of quoted items (certificate duly attested by senior executive of the firm). | 5 | |
| 6 | Adequate number of qualified persons and relevant Human resource (Certificate duly attested by the senior executive of the firm) | 5 | |
| 7 | Good Declaration certificate of imported finished item/s by the firm from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than ONE year (Certificate duly attested by the senior executive of the firm) | 5 | |
| 8 | Certificate of analysis of imported finished quoted items from principal manufacturer (Certificate duly attested by the senior executive of the firm) | 5 | |
| 9 | Valid Calibration Certificate for equipment in the manufacturing unit in the country of origin (certificate duly attested by senior executive of the firm). | 5 | |
| 10 | Availability of quoted items in Pakistani Market as per recent most data of IQIA/ IMS Data (1-20% shares=2 mark, 21-40%=3 marks, 41% and above=5marks) | 5 | |
| 11 | Stability studies of quoted items (certificate duly attested by the Quality control manager of the firm) | 5 | |
| 12 | Last Year performance of the firm – 02 marks for each performance certificate issued by relevant authority of the hospital with a capacity of 250 beds or above <i>(To be verified by technical evaluation committee).</i> | 10 | |
| FINANCIAL EVALUATION | | | |
| 12 | Quoted unit Price | 30 | |
| 13 | Lowest Quoted Unit Price among the qualified bids for particular item | | |
| 14 | Maximum Allocable Unit Price Score | | |
| 15 | Score awarded to the unit price of quoted item | | |
| TOTAL MARKS | | 100 | |

B-2. Evaluation Criteria for Importer of MEDICINE for LRH-MTI Peshawar 2024-2025

Firm / Company Name:

| S.No. | Parameters | Marks | Remarks |
|-----------------------------|--|-------|---------|
| TECHNICAL EVALUATION | | | |
| 1 | Current export certificate of the quoted items from DRAP not older than TWO year <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 2 | Valid ISO 14001 certificate from PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 3 | Valid ISO 9001 certificate from PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 4 | Valid ISO 13485 certificate from PNAC accredited body <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 5 | Adherence to Good storage practices (GSP) duly verified by DRAP/Authorized body for finished goods storage of the quoted item(s) (certificate duly attested by the senior executive of the firm) | 5 | |
| 6 | Adequate number of qualified persons and relevant Human resource (Certified duly attested by the senior executive of the firm) | 5 | |
| 7 | Goods Declaration certificate of imported APIs of quoted items from Pakistan Customs, not older than ONE year (Certificate duly attested by the senior executive of the firm) | 5 | |
| 8 | Certificate of analysis of finished goods of the quoted item(s) (duly attested by senior executive of the firm). | 5 | |
| 9 | Physical examination of the quoted item/s by the LRH-MTI expert committee. (Excellent=20, Good=10, satisfactory=5); non-recommendation shall lead to disqualification | 20 | |
| 10 | Last Year performance of the firm – 02 marks for each performance certificate issued by relevant authority of the hospital with a capacity of 250 beds or above <i>(To be verified by technical evaluation committee).</i> | 10 | |
| FINANCIAL EVALUATION | | | |
| 11 | Quoted unit Price | 30 | |
| 12 | Lowest Quoted Unit Price among the qualified bids for particular item | | |
| 13 | Maximum Allocable Unit Price Score | | |
| 14 | Score awarded to the unit price of quoted item | | |
| TOTAL MARKS | | 100 | |

2. Evaluation Criteria for Importers of NON-DRUG ITEMS for LRH-MTI Peshawar 2024-2025

| Firm / Company Name: | | | |
|-----------------------------|---|-------|---------|
| S.No. | Parameters | Marks | Remarks |
| TECHNICAL EVALUATION | | | |
| 1 | Valid ISO 9001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 2 | Valid ISO 13485 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 3 | Valid ISO 14001 certificate issued by authorized body of the country of origin <i>(To be verified by technical evaluation committee).</i> | 5 | |
| 4 | Certificate of Adherence to Good Storage practices (GSP) duly verified by DRAP/Authorized body for finished Goods and storage of quoted items (certificate duly attested by senior executive of the firm). | 5 | |
| 5 | Adequate number of qualified persons and relevant Human resource (Certificate duly attested by the senior executive of the firm) | 5 | |
| 6 | Good Declaration certificate of imported finished item/s by the firm from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than ONE year (Certificate duly attested by the senior executive of the firm) | 5 | |
| 7 | Certificate of analysis of imported finished goods of the quoted items from principal manufacturer, not older than ONE year (Certificate duly attested by the senior executive of the firm) | 5 | |
| 8 | Valid Calibration Certificate for equipment in the manufacturing unit in the country of origin (certificate duly attested by senior executive of the firm). | 5 | |
| 9 | Physical examination of the quoted item/s by the LRH-MTI expert committee. (Excellent=20, Good=10, satisfactory=5); non-recommendation shall lead to disqualification | 20 | |
| 10 | Last Year performance of the firm – 02 marks for each performance certificate issued by relevant authority of the hospital with a capacity of 250 beds or above <i>(To be verified by technical evaluation committee).</i> | 10 | |
| FINANCIAL EVALUATION | | | |
| 12 | Quoted unit Price | 30 | |
| 13 | Lowest Quoted Unit Price among the qualified bids for particular item | | |
| 14 | Maximum Allocable Unit Price Score | | |
| 15 | Score awarded to the unit price of quoted item | | |
| TOTAL MARKS | | 100 | |

SECTION V. BLACKLISTING AND DEBARMENT

Conditions for Blacklisting of Defaulting Bidder (Contractor under rule 44 of KPPRA Rules 2014)

The following are the events which shall lead to initiate blacklisting/debarment process as per Rule 44 of KPPRA Rules 2014,

Consistent failure to provide satisfactory performances.

Found involved in corrupt/fraudulent practices.

Abandoned the place of work permanently

Conditions for debarment of Defaulting Bidder/Contractor

Failure or refusal to;

Accept Purchases Order / Services order terms;

Make supplies as per specifications agreed:

Fulfill contractual obligations as per contract

Non execution of work as per terms & condition of contract.

Any unethical or unlawful professional or business behavior detrimental to good conduct and integrity of the public procurement process.

Persistent and intentional violation of important conditions of contract.

Non-adherence to quality specifications despite being importunately pointed out.

Security consideration of the State i.e., any action that jeopardizes the security of the State or good repute of the Lady Reading Hospital MTI Peshawar.

Procedure for Blacklisting and debarment

Competent authority of Lady Reading Hospital MTI Peshawar may on information, or on its own motion, issue show cause notice to the bidder.

The show-cause notice shall contain the statement of allegation against the Bidder.

The bidder will be given maximum of seven days to submit the written reply of the show cause notice.

In case the bidder fails to submit written reply within the requisite time, the competent authority may proceed forth with ex-parte against the bidder.

Direct to issue notice of personal hearing to the bidder/ authorized representative of the bidder and the competent authority shall decide the matter on the basis of available record and personal hearing, if availed. The competent authority shall decide the matter within thirty days from the initiation of proceedings.

The order of competent authority shall be communicated to the bidder by indicating reasons.

The order past as above shall be duly conveyed to the PKPRA and defaulting bidder within three days of passing order.

The duration of debarment may vary up to five years depending upon the nature of violation.

REDRESSING OF GRIEVANCES

The purchaser shall designate and notify a grievance redressal officer empowered to address the complaints of bidders have been filed against the procuring entity.

Any bidder feeling aggrieved by act of the purchaser after the submission of his bid may lodge a written complaint concerning his grievances not later than 03 days after the announcement of the bid evaluation report.

The grievance redressal Officer shall investigate and decide upon the complaint within 06 days of the receipt of the complaint. The report along with decision shall be forwarded to the purchase officer within the prescribed period.

Mere fact of lodging of a complaint shall not warrant suspension of the procurement process.

Note: Grievance notified & designated who can invite appropriate official as co-opted member for grievance.

Section VI: SCHEDULE OF REQUIREMENT

| MEDICAL ITEMS | | |
|---|----------------------------------|------------------------|
| Formulary.No. | GENERIC NAME | DOSAGE FORM/ STRENGTH |
| ANESTHESIA DRUGS | | |
| 1 | Atracurium Besylate | Injection 3ml |
| 2 | Atracurium Besylate | Injection 5ml |
| 3 | Bupivacaine Hydrochloride | Injection 5mg |
| 4 | Bupivacaine Hydrochloride Spinal | inj 7.5mg |
| 5 | Dexmedetomidine | Injection 0.1mg/ml |
| 6 | Glycopyrrolate | Injection 0.2 mg/ml |
| 7 | Glycopyrrolate / Neostigmine | Injection 0.5+2.5mg/ml |
| 8 | Isoflurane | Liquid 100ml |
| 9 | Isoflurane | Liquid 250ml |
| 10 | Ketamine | Injection 50 mg/ml |
| 11 | Lignocaine | Injection 2% 10 ml |
| 12 | Lignocaine with adrenaline | Injection 10ml |
| 13 | Neostigmine Methylsulphate | Injection 2.5 mg |
| 14 | Propofol | Injection 10mg/ml |
| 15 | Succinylcholine / Suxamethonium | Injection 50mg/ml |
| ANALGESICS, ANTI INFLAMMATORY AND ANTIPYRETICS | | |
| 16 | Diclofenac Sodium | Tablets 25mg |
| 17 | Diclofenac Sodium | Tablets 50mg |
| 18 | Diclofenac Sodium | Tablets SR 100mg |
| 19 | Diclofenac Sodium | Injection 75mg/3ml |
| 20 | Diclofenac Sodium | Suppository 25mg |
| 21 | Diclofenac Sodium | Suppository 100mg |
| 22 | Ibuprofen | Tablet 200mg |
| 23 | Ibuprofen | Tablet 400mg |
| 24 | Ibuprofen | Suspension 100mg/5ml |
| 25 | Ibuprofen | Suspension 200mg/5ml |
| 26 | Ibuprofen | Infusion 400mg/100ml |
| 27 | Indomethacin | Tab 25mg |
| 28 | Indomethacin | Cap 25mg |
| 29 | Indomethacin | Injection 50mg |

| | | |
|------------------|-------------------|-------------------------|
| 30 | Ketorolac | Injection 30mg/ml |
| 31 | Mefenamic acid | Tablet 250 mg |
| 32 | Mefenamic acid | Tablet 500 mg |
| 33 | Mefenamic acid | Susp 50mg |
| 34 | Mefenamic acid | Susp 100mg |
| 35 | Nalbuphine | injection 10mg |
| 36 | Nalbuphine | injection 20mg |
| 37 | Paracetamol | Suspension 120 ml |
| 38 | Paracetamol | Suspension 100 ml |
| 39 | Paracetamol | Suspension 250 mg/ 5 ml |
| 40 | Paracetamol | Tablet 500 mg |
| 41 | Paracetamol | Tablet 665mg |
| 42 | Paracetamol | Drops 30ml |
| 43 | Paracetamol | Infusion 1gm/100 ml |
| 44 | Paracetamol | Suppository |
| 45 | Tramadol | Injection 50mg/ml |
| 46 | Tramadol | Tab 50mg |
| 47 | Tramadol | Tab 100mg |
| ANTIDOTES | | |
| 48 | Acetylcystine | Injection 200mg/ml |
| 49 | Acetylcystine | Powder 200mg |
| 50 | Activated charcol | Powder |
| 51 | Activated charcol | Tablets |
| 52 | Deferasirox | Tablet 500mg |
| 53 | Deferasirox | Tablet 400mg |
| 54 | Deferasirox | Tablet 250mg |
| 55 | Deferasirox | Tablet 100mg |
| 56 | Deferoxamine | Injection 500mg |
| 57 | Dimercaprol | Injection 50mg/ml |
| 58 | Flumazini | Injection 100 mcg/ml |
| 59 | Fomepizole | Injection 1gm/ml |
| 60 | Glucagon | Injection 200mg |
| 61 | Levoleucovorin | Injection 50mg/ml |
| 62 | Naloxone | Injection 0.4mg/ml |
| 63 | Naltrexone | Injection 380mg |
| 64 | Pralidoxime | Injection 20mg/ml |

| | | |
|---|------------------------------------|----------------------|
| 65 | Protamin Sulphate | Injection 10mg/ml |
| 66 | Phytomenadione (Vitamin K) | Injection 2mg/ml |
| ANTI FUNGAL DRUGS | | |
| 67 | Amphotericin b | Injection 50 mg |
| 68 | Fluconazole | Infusion 2mg/ml |
| 69 | Fluconazole | Capsule 150mg |
| 70 | Fluconazole | Capsule 50mg |
| 71 | Voriconazole | Injection 200 mg |
| 72 | Voriconazole | Tablet 200 mg |
| ANTI HISTAMINE AND ANTI ALLERGIC DRUGS | | |
| 73 | Ebastine | Tab 10mg |
| 74 | Ebastine | Tab 20 mg |
| 75 | Ebastine | Syp 5mg |
| 76 | Levocetirizine | Tablet 5mg |
| 77 | Levocetirizine | Tablet 10mg |
| 78 | Levocetirizine | Syrup 2.5mg/5ml |
| 79 | Loratidine | Tab 10mg |
| 80 | Loratidine | Syp 1mg/ml |
| 81 | Pheniramine Maleate | Injection 4 ml |
| 82 | Prochlorperazine | Injection 12.5mg/nl |
| 83 | Prochlorperazine | Tablet 5 mg |
| ANTIBACTERIAL DRUGS | | |
| 84 | Amikacin | Injection 25mg |
| 85 | Amikacin | Injection 50mg |
| 86 | Amikacin | Injection 100mg |
| 87 | Amikacin | Injection 250mg |
| 88 | Amikacin | Injection 500mg |
| 89 | Amoxicillin Sodium/Clavulanic Acid | Injection 1.2gm |
| 90 | Amoxicillin Sodium/Clavulanic Acid | Injection 0.6gm |
| 91 | Amoxicillin Sodium/Clavulanic Acid | Tablet 1 gm |
| 92 | Amoxicillin Sodium/Clavulanic Acid | Tablet 625mg |
| 93 | Amoxicillin Sodium/Clavulanic Acid | Tablet 375mg |
| 94 | Amoxicillin Sodium/Clavulanic Acid | Suspension 312.50mg |
| 95 | Amoxicillin Sodium/Clavulanic Acid | Suspension 156.25mg |
| 96 | Amoxicillin Sodium/Clavulanic Acid | Suspension 457mg |
| 97 | Amoxicillin Sodium/Clavulanic Acid | Drop 62.5mg |
| 98 | Ampicillin | Injection 250mg/vial |

| | | |
|------------|---------------------------------|---------------------------|
| 99 | Ampicillin | Injection 500mg/vial |
| 100 | Ampicillin | Injection 1 gm/vial |
| 101 | Azithromycin | Injection 500mg |
| 102 | Azithromycin | Tablet 500mg |
| 103 | Azithromycin | Tablet 250mg |
| 104 | Azithromycin | Cap 500mg |
| 105 | Azithromycin | Dry Suspension 100 mg/5ml |
| 106 | Azithromycin | Dry Suspension 200 mg/5ml |
| 107 | Azithromycin | Cap 250mg |
| 108 | Benzylpenicillin (Penicillin g) | Injection 10 lac unit |
| 109 | Benzylpenicillin (Penicillin g) | Injection 5 lac unit |
| 110 | Cefaclor | Cap 250mg |
| 111 | Cefaclor | Cap 500mg |
| 112 | Cefaclor | Tab 375mg |
| 113 | Cefaclor | Tab 750mg |
| 114 | Cefaclor | Syp 125mg/5ml |
| 115 | Cefaclor | Syp 250mg/5ml |
| 116 | Cefaclor | Syp 187mg |
| 117 | Cefaclor | Drops 50mg |
| 118 | Cefaclor | Drops 100mg |
| 119 | Cefazolin | Inj 250mg |
| 120 | Cefazolin | Injection 500mg |
| 121 | Cefazolin | Injection 1gm |
| 122 | Cefepime | Injection 500mg |
| 123 | Cefepime | Injection 1gm |
| 124 | Cefixime | Dry Suspension 100mg/5ml |
| 125 | Cefixime | Dry Suspension 200mg/5ml |
| 126 | Cefixime | Capsule 400mg |
| 127 | Cefixime | Tab 200mg |
| 128 | Cefoparazone Sodium/ Salbactum | Injection 500mg/vial |
| 129 | Cefoparazone Sodium/ Salbactum | Injection 1gm/vial |
| 130 | Cefoparazone Sodium/ Salbactum | Injection 2gm/vial |
| 131 | Cefotaxime Sodium | Injection 1gm/vial |
| 132 | Cefotaxime Sodium | Injection 250mg/vial |
| 133 | Cefotaxime Sodium | Injection 500mg/vial |
| 134 | Ceftazidime | Injection 250mg |

| | | |
|------------|-----------------------|----------------------|
| 135 | Ceftazidime | Injection 500mg |
| 136 | Ceftazidime | Injection 1gm |
| 137 | Ceftriaxone Sodium | Injection 250mg/vial |
| 138 | Ceftriaxone Sodium | Injection 500mg/vial |
| 139 | Ceftriaxone Sodium | Injection 1gm/vial |
| 140 | Ceftriaxone Sodium | Injection 2 gm/vial |
| 141 | Cefuroxime | Injection 750mg |
| 142 | Cefuroxime | Injection 1.5gm |
| 143 | Cefuroxime | Tab 125mg |
| 144 | Cefuroxime | Tab 250mg |
| 145 | Cefuroxime | Tab 500mg |
| 146 | Cefuroxime | Susp 125mg |
| 147 | Cefuroxime | Susp 250mg |
| 148 | Cephradine | Inj 250mg |
| 149 | Cephradine | Inj 500mg |
| 150 | Cephradine | Inj 1gm |
| 151 | Cephradine | Cap 250mg |
| 152 | Cephradine | Cap 500mg |
| 153 | Cephradine | Syp 125mg |
| 154 | Cephradine | Syp 250mg/5ml |
| 155 | Ciprofloxacin | Tablet 250 mg |
| 156 | Ciprofloxacin | Tablet 500 mg |
| 157 | Ciprofloxacin | Infusion 200mg/100ml |
| 158 | Ciprofloxacin | Infusion 400mg/100ml |
| 159 | Ciprofloxacin | Susp 125mg |
| 160 | Ciprofloxacin | Susp 250mg |
| 161 | Clarithromycin | Injection 500mg |
| 162 | Clarithromycin | Tab 250mg |
| 163 | Clarithromycin | Tablets 500mg |
| 164 | Clarithromycin | Suspension 250mg/5ml |
| 165 | Clarithromycin | Suspension 125mg/5ml |
| 166 | Clarithromycin | Drops 125mg |
| 167 | Colistimethate Sodium | Injection 1MU |
| 168 | Colistimethate Sodium | Injection 2MU |
| 169 | Colistimethate Sodium | Injection 3MU |
| 170 | Clindamycin | Cap 150mg |

| | | |
|------------|---------------------------|-----------------------|
| 171 | Clindamycin | Cap 300mg |
| 172 | Clindamycin | Injection 150mg/ml |
| 173 | Doxycycline | Cap 100mg |
| 174 | Doxycycline | Tab 100mg |
| 175 | Gentamicin | Injection 20mg |
| 176 | Gentamicin | Injection 40mg |
| 177 | Gentamicin | Injection 80mg |
| 178 | Gentamicin | Eye drops 0.3% |
| 179 | Gentamicin | Ear drops 0.3% |
| 180 | Imepinime + Cilastatin | Injection 500 mg |
| 181 | Levofloxacin | Infusion 750mg |
| 182 | Levofloxacin | Infusion 500mg |
| 183 | Levofloxacin | Tab 250mg |
| 184 | Levofloxacin | Tab 500mg |
| 185 | Levofloxacin | Tab 750mg |
| 186 | Lincomycin | Inj 300mg |
| 187 | Lincomycin | Inj 600mg |
| 188 | Lincomycin | Cap 500mg |
| 189 | Lincomycin | Susp 250mg |
| 190 | Linezolid | Infusion 2mg/ml 100ml |
| 191 | Linezolid | Infusion 2mg/ml 300ml |
| 192 | Linezolid | Tab 400mg |
| 193 | Linezolid | Tablet 600mg |
| 194 | Linezolid | Susp 100mg |
| 195 | Meropenem | Injection 500 mg |
| 196 | Meropenem | Injection 1gm |
| 197 | Metronidazole | Infusion 500mg/100 ml |
| 198 | Metronidazole | Suspension 200mg /5ml |
| 199 | Metronidazole | Tab 200mg |
| 200 | Metronidazole | Tab 400mg |
| 201 | Moxifloxacin | Infusion 400mg/250 ml |
| 202 | Moxifloxacin | Tablet 400mg |
| 203 | Moxifloxacin | Eye Drops 0.5% w/v |
| 204 | Piperacillin + Tazobactam | Injection 2.25 gm |
| 205 | Piperacillin + Tazobactam | Injection 4.5 gm |
| 206 | Rifaximin | Tablet 550 mg |

| | | |
|----------------------------|---------------------------------|---------------------------|
| 207 | Rifaximin | Tablet 200 mg |
| 208 | Tigecycline | Injection 50mg |
| 209 | Tobramycin | Injection 10mg |
| 210 | Tobramycin | Injection 20mg |
| 211 | Tobramycin | Injection 80mg |
| 212 | Tobramycin | Eye Oint 0.3% |
| 213 | Tobramycin | Eye Drops 0.3% |
| 214 | Trimethoprim / Sulfamethoxazole | Tab 80mg/400mg |
| 215 | Trimethoprim / Sulfamethoxazole | Tab 160mg/800mg |
| 216 | Trimethoprim / Sulfamethoxazole | Susp 40mg/200mg |
| 217 | Trimethoprim / Sulfamethoxazole | Susp 80mg/400mg |
| 218 | Vancomycin | Injection 500 mg |
| 219 | Vancomycin | Injection 1gm |
| ANTI VIRAL DRUGS | | |
| 220 | Acyclovir | Inj 250mg |
| 221 | Acyclovir | Inj 500mg |
| 222 | Acyclovir | Cream 5% |
| 223 | Acyclovir | Oint 5% |
| 224 | Acyclovir | Susp 200mg |
| 225 | Acyclovir | Tab 200mg |
| 226 | Acyclovir | Tab 400mg |
| 227 | Acyclovir | Tab 800mg |
| 228 | Ganciclovir | Inj 250mg |
| 229 | Ganciclovir | Inj 500mg |
| ANTI MALARIAL DRUGS | | |
| 230 | Artemether | Injection 80mg |
| 231 | Artemether / Lumefantrine | Tablet 80mg+480 mg |
| 232 | Artemether / Lumefantrine | Tablet 40mg+240 mg |
| 233 | Artemether / Lumefantrine | Suspension 15mg+90mg/5ml |
| 234 | Artemether / Lumefantrine | Tab 20mg + 120mg |
| 235 | Artemether / Lumefantrine | Suspension 30mg+180mg/5ml |
| 236 | Artesunate | Inj 30mg |
| 237 | Artesunate | Inj 60mg |
| 238 | Artesunate | Inj 120mg |
| 239 | Chloroquine | Syrup 50 mg/5 ml |
| 240 | Chloroquine | Tablet 250mg |

| | | |
|---|--|-----------------------|
| 241 | Chloroquine | Inj 200mg/5ml |
| 242 | Dihydroartemisinin & Piperaquine Phosphate | Capsule 40/320mg |
| 243 | Dihydroartemisinin & Piperaquine Phosphate | Sachet 15mg/120mg |
| 244 | Primaquine | Tablet 7.5mg |
| 245 | Quinine sulphate | Tab 300mg |
| BLOOD FORMING DRUGS, COAGULANTS, ANTI-COAGULANTS AND ANTI-ANEMIC DRUGS | | |
| 246 | Enoxaparin | Injection 20 mg |
| 247 | Enoxaparin | Injection 40mg |
| 248 | Enoxaparin | Injection 60mg |
| 249 | Enoxaparin | Injection 80mg |
| 250 | Epoetin Alpha | Injection 2000 IU |
| 251 | Epoetin Alpha | Injection 4000 IU |
| 252 | Epoetin Alpha | Injection 10000 IU |
| 253 | Epoetin Beta | Injection 2000 IU |
| 254 | Epoetin Beta | Injection 5000 IU |
| 255 | Epoetin Beta | Injection 10000 IU |
| 256 | Factor VII | Injection 1gm/ Vial |
| 257 | Factor VIII | Injection 250 IU/Vial |
| 258 | Ferrous sulphate | Tablet 200mg |
| 259 | Ferrous sulphate | Syp 100mg |
| 260 | Folic Acid | Tablet 5mg |
| 261 | Fondaparinux sodium | Injection 7.5mg |
| 262 | Fondaparinux sodium | Injection 2.5mg |
| 263 | Gelatin polypeptide | Infusion 4% 500 ml |
| 264 | Gelatin polypeptide | Infusion 3.5% 500 ml |
| 265 | Heparin | Injection 5000 IU/ml |
| 266 | Iron Polymaltose Complex | Syrup 50mg/5 ml |
| 267 | Iron Sucrose | Injection 100mg/5 ml |
| 268 | Mecobalamin | Injection 500mcg |
| 269 | Mecobalamin | Tab 500mcg |
| 270 | Mecobalamin | Tab. 1000mcg |
| 271 | Rivaroxaban | Tab 2.5mg |
| 272 | Rivaroxaban | Tab 10mg |
| 273 | Rivaroxaban | Tab 15mg |
| 274 | Rivaroxaban | Tab 20 mg |
| 275 | Tirofiban | Infusion 50ml |

| | | |
|--|---------------------------------|------------------|
| 276 | Tranexamic Acid | Injection 250mg |
| 277 | Tranexamic Acid | Injection 500mg |
| 278 | Tranexamic Acid | Injection 1 gm |
| 279 | Tranexamic Acid | Tab 250mg |
| 280 | Tranexamic Acid | Tab 500mg |
| 281 | Tranexamic Acid | Capsule 250mg |
| 282 | Tranexamic Acid | Capsule 500mg |
| 283 | Warfarin Sodium | Tablet 5mg |
| CARDIOVASCULAR AND DIURETIC DRUGS | | |
| 284 | Acetyl Salicylic Acid - Aspirin | Tab 150mg |
| 285 | Acetyl Salicylic Acid - Aspirin | Tab 300mg |
| 286 | Acetyl Salicylic Acid - Aspirin | Tablet 75 mg |
| 287 | Adrenalin / Epinephrine | Injection 1mg/ml |
| 288 | Alteplase | Injection 50mg |
| 289 | Amiodarone | Injection 150mg |
| 290 | Amiodarone | Tablet 100mg |
| 291 | Amiodarone | Tablet 200mg |
| 292 | Amlodipine Besylate | Tab 2.5mg |
| 293 | Amlodipine Besylate | Tablet 5 mg |
| 294 | Amlodipine Besylate | Tablet 10mg |
| 295 | Atropine | Injection 1mg/ml |
| 296 | Bisoprolol | Tablet 5mg |
| 297 | Bisoprolol | Tablet 2.5mg |
| 298 | Bisoprolol | Tablet 10mg |
| 299 | Candesartan | Tablet 8 mg |
| 300 | Candesartan | Tablet 16mg |
| 301 | Candesartan | Tablet 4mg |
| 302 | Candesartan | Tablet 32mg |
| 303 | Captopril | Tablet 25mg |
| 304 | Captopril | Tablet 50mg |
| 305 | Captopril | Tablet 12.5 mg |
| 306 | Carvedilol | Tablet 3.125 mg |
| 307 | Carvedilol | Tablet 6.25mg |
| 308 | Carvedilol | Tablet 12.5mg |
| 309 | Carvedilol | Tablet 25mg |
| 310 | Clopidogrel | Tablet 75mg |

| | | |
|------------|------------------------|---------------------|
| 311 | Clopidogrel | Tablet 300mg |
| 312 | Clopidogrel + Asprin | Tablet 75/75mg |
| 313 | Clopidogrel + Asprin | Tablet 75/150mg |
| 314 | Digoxin | Injection 0.5mg 2ml |
| 315 | Digoxin | Tablets 250mcg |
| 316 | Dobutamine | Injection 250mg/5ml |
| 317 | Dopamine | injection 200mg/5ml |
| 318 | Frusemide | Injection 10mg/ml |
| 319 | Frusemide | Tablet 20mg |
| 320 | Frusemide | Tablet 40mg |
| 321 | Glyceryl trinitrate | Injection 1mg/ml |
| 322 | Glyceryl trinitrate | Tablet SL 0.5mg |
| 323 | Glyceryl trinitrate | Tablet 2.6mg |
| 324 | Glyceryl trinitrate | Tablet 6.4mg |
| 325 | Hydralazine | Injection 20 mg |
| 326 | Hydralazine | Tablet 25mg |
| 327 | Hydralazine | Tablet 50mg |
| 328 | Hydrochlorothiazide | Tablet 25mg |
| 329 | Isoprenaline | Injection 1mg/ml |
| 330 | Isosorbide Dinitrate | Injection 1mg/ml |
| 331 | Isosorbide Dinitrate | Cap 40mg |
| 332 | Isosorbide Dinitrate | Tablet 10mg |
| 333 | Isosorbide Mononitrate | Tablet 20 mg |
| 334 | Isosorbide Mononitrate | Tablet 40mg |
| 335 | Isosorbide Mononitrate | Tablet 10mg |
| 336 | Isosorbide Mononitrate | Tablet 60mg |
| 337 | Labetalol | Injection 50mg |
| 338 | Labetalol | Tab 100mg |
| 339 | Lisinopril | Tab 5mg |
| 340 | Lisinopril | Tab 10mg |
| 341 | Lisinopril | Tab 20mg |
| 342 | Losartan | Tab 25mg |
| 343 | Losartan | Tab 50mg |
| 344 | Losartan | Tab 100mg |
| 345 | Midodrine | Tab 5mg |
| 346 | Milrinone Lactate | 1mg/ml |

| | | |
|------------|--------------------------------|------------------------|
| 347 | Methyldopa | Tablet 250 mg |
| 348 | Methyldopa | Injection 250 mg |
| 349 | Metoprolol | Injection 5 mg |
| 350 | Metoprolol | Tablet 25mg |
| 351 | Metoprolol | Tablet 50mg |
| 352 | Metoprolol | Tablet 100mg |
| 353 | Metoprolol | Tab 200mg |
| 354 | Nifedipine | Capsule 10mg |
| 355 | Nifedipine | Tab 10mg |
| 356 | Nifedipine | Tab 20mg |
| 357 | Nifedipine | Tablet 30mg |
| 358 | Nifedipine | Tab 60mg |
| 359 | Nimodipine | Tablet 30mg |
| 360 | Nimodipine | Injection 10mg |
| 361 | Noradrenaline / Norepinephrine | Injection 1mg/ml |
| 362 | Propranolol | Tablet 40mg |
| 363 | Propranolol | Tablet 10mg |
| 364 | Ramipril | Tablet 1.25mg |
| 365 | Ramipril | Tablet 2.5mg |
| 366 | Ramipril | Tablet 5mg |
| 367 | Ramipril | Tablet 10mg |
| 368 | Rosuvastatin | Tablet 5 mg |
| 369 | Rosuvastatin | Tablet 10 mg |
| 370 | Rosuvastatin | Tablet 20 mg |
| 371 | Sacubitril / Valsartan | Tablet 50 mg |
| 372 | Sacubitril / Valsartan | Tablet 100 mg |
| 373 | Sacubitril / Valsartan | Tablet 200mg |
| 374 | Sodium Nitroprusside | Injection 50mg |
| 375 | Spironolactone | Tab 25mg |
| 376 | Spironolactone | Tablet 100mg |
| 377 | Spironolactone / Frusemide | Tablets 20mg |
| 378 | Spironolactone / Frusemide | Tablets 40mg |
| 379 | Streptokinase | Injection 1.5 MIU/vial |
| 380 | Valsartan | Tablet 80mg |
| 381 | Valsartan | Tablet 160mg |
| 382 | Valsartan | Tablet 40mg |

| | | |
|--------------------------------|---------------------------------|-------------------|
| 383 | Valsartan | Tablet 320mg |
| 384 | Valsartan / Hydrochlorothiazide | Tab 160/12.5 mg |
| 385 | Valsartan / Hydrochlorothiazide | Tab 160/25 mg |
| 386 | Valsartan / Hydrochlorothiazide | Tab 80/12.5 mg |
| 387 | Verapamil | Tablet 40mg |
| 388 | Verapamil | Tablet 80mg |
| 389 | Verapamil | Tab 240mg |
| 390 | Verapamil | Injection 2.5mg |
| GASTRO INTESTINAL DRUGS | | |
| 391 | Dimenhydrinate | Injection 50mg/ml |
| 392 | Dimenhydrinate | Tablet 50mg |
| 393 | Dimenhydrinate | Syrup 12.5mg/4ml |
| 394 | Domperidone | Tab 10mg |
| 395 | Domperidone | Syp 120ml |
| 396 | Drotaverine | Injection 40mg |
| 397 | Drotaverine | Tablet 40mg |
| 398 | Drotaverine | Tab 80mg |
| 399 | Famotidine | Tablet 20mg |
| 400 | Famotidine | Tablet 40mg |
| 401 | Famotidine | Injection 40mg |
| 402 | Famotidine | Syp 10mg/5ml |
| 403 | Famotidine | Syp 40mg/5ml |
| 404 | Lactulose | Syrup 120 ml |
| 405 | Lactulose | Syrup 240 ml |
| 406 | Levosulpiride | Tablet 25mg |
| 407 | Levosulpiride | Tablet 50mg |
| 408 | Levosulpiride | Tablet 100mg |
| 409 | Loperamide | Tablet 2mg |
| 410 | Loperamide | Cap 2mg |
| 411 | Metoclopramide | Injection 10mg |
| 412 | Metoclopramide | Syrup 5mg/5ml |
| 413 | Metoclopramide | Tablet 10mg |
| 414 | Metoclopramide | Drops 1mg/ml |
| 415 | Octreotide Acetate | Injection 100mcg |
| 416 | Octreotide Acetate | Injection 500mcg |
| 417 | Octreotide Acetate | Injection 50 mcg |

| | | |
|---|--|----------------------|
| 418 | Octreotide Acetate | Injection LAR 20mg |
| 419 | Octreotide Acetate | Injection LAR 30mg |
| 420 | Omeprazole | Infusion 40 mg |
| 421 | Omeprazole | Capsule 40mg |
| 422 | Omeprazole | Capsule 20mg |
| 423 | Ondansetron | Injection 2mg/ml |
| 424 | Ondansetron | Tablet 8mg |
| 425 | Ondansetron | Syp 4mg |
| 426 | Pantoprazole | Tablet 20mg |
| 427 | Pantoprazole | Tablet 40mg |
| 428 | Pantoprazole | Injection 40mg |
| 429 | Phloroglucinol & Trimethylphloroglucinol | Tab 80mg |
| 430 | Phloroglucinol & Trimethylphloroglucinol | Injection 4ml |
| 431 | Sodium Biphosphate + Sodium Phosphate | Enema |
| 432 | Terlipressin | Injection 1mg |
| 433 | Zinc Sulphate | Syrup 20 mg/5 ml |
| 434 | Zinc Sulphate | Tablet 10mg |
| 435 | Zinc Sulphate | Tablet 20mg |
| HARMONES, ANALOGUES AND DRUGS ACTING ON ENDOCRINE SYSTEM | | |
| 436 | Insulin Glargine | Injection 100 IU/ ml |
| 437 | Insulin Human 70/30 | Injection 100 IU/ ml |
| 438 | Insulin Lispro | Injection 100 IU/ ml |
| 439 | Insulin Regular (Human) | Injection 100 IU/ ml |
| 440 | Desmopressin | Tab 0.1 mg |
| 441 | Desmopressin | Tab 0.2 mg |
| 442 | Desmopressin | Inj 4 mcg/ml |
| 443 | Dinoprostone | Tab Vaginal 3mg |
| 444 | Dapagliflozin | Tab 5mg |
| 445 | Dapagliflozin | Tab 10mg |
| 446 | Dapagliflozin / Metformin | Tablet 5/500 |
| 447 | Dapagliflozin / Metformin | Tablet 5/850 |
| 448 | Dapagliflozin/ Metformin | Tablet 5/1000 |
| 449 | Dexamethasone | Injection 4 mg /ml |
| 450 | Dexamethasone | Tablet 0.5mg |
| 451 | Dexamethasone | Eye drops 0.1% |
| 452 | Dexamethasone | Eye Oint 0.1% |

| | | |
|------------|---------------------------------|--------------------|
| 453 | Empagliflozin | Tab 10mg |
| 454 | Empagliflozin | Tab 25mg |
| 455 | Empagliflozin/ metformin | Tablet12.5/ 500mg |
| 456 | Empagliflozin/ metformin | Tablet12.5/ 1000mg |
| 457 | Fludrocortisone | Tab 0.1mg |
| 458 | Glibenclamide | Tab 5mg |
| 459 | Gliclazide | Tab 30mg |
| 460 | Gliclazide | Tab 60mg |
| 461 | Gliclazide | Tab 80mg |
| 462 | Gliclazide | Tab 90mg |
| 463 | Glimepride | Tablet 1mg |
| 464 | Glimepride | Tablet 2mg |
| 465 | Glimepride | Tablet 3mg |
| 466 | Glimepride | Tablet 4mg |
| 467 | Hydrocortisone Sodium Succinate | Injection 100 mg |
| 468 | Hydrocortisone Sodium Succinate | Injection 250 mg |
| 469 | Hydrocortisone Sodium Succinate | Injection 500 mg |
| 470 | Hydrocortisone Sodium Succinate | Oint 1% |
| 471 | Hydrocortisone Sodium Succinate | Cream 1% |
| 472 | Metformin | Tablet 250mg |
| 473 | Metformin | Tablet 500mg |
| 474 | Metformin | Tablet 850mg |
| 475 | Metformin | Tablet 1gm |
| 476 | Metformin | Tablet XR 1gm |
| 477 | Metformin | Tablet XR 750mg |
| 478 | Metformin | Tablet XR 500mg |
| 479 | Methyl Prednisolone | Injection 500 mg |
| 480 | Methyl Prednisolone | Injection 1g |
| 481 | Methyl Prednisolone | Inj 40mg |
| 482 | Misoprostol | Tablet 200 mcg |
| 483 | Misoprostol / Diclofenac | Tablet 200/50 |
| 484 | Oxytocin | Injection 5 IU/ml |
| 485 | Oxytocin | Injection 10 IU/ml |
| 486 | Prednisolone | |
| 487 | Progesterone | Injection 10 mg |
| 488 | Sitagliptin / Metformin | Tablets 50mg/500mg |

| | | |
|---|--|---------------------------|
| 489 | Sitagliptin / Metformin | Tablets 50mg/850mg |
| 490 | Sitagliptin / Metformin | Tablets 50mg/1000mg |
| 491 | Sitagliptin / Metformin | Tablets 100mg/1000mg |
| 492 | Thyroxin Sodium | Tablet 25mcg |
| 493 | Thyroxin Sodium | Tablet 50mcg |
| 494 | Thyroxin Sodium | Tablet 75mcg |
| 495 | Thyroxin Sodium | Tablet 100mcg |
| 496 | Thyroxin Sodium | Tablet 125mcg |
| 497 | Vasopressin | Inj 20 Units/ml |
| 498 | Vildagliptin / Metformin | Tab 50mg/500mg |
| 499 | Vildagliptin / Metformin | Tablets 50mg/850mg |
| 500 | Vildagliptin / Metformin | Tablets 50mg/1000mg |
| IMMUNOLOGICAL DRUGS | | |
| 501 | Anti Rabies Vaccine | Injection 1000IU |
| 502 | Filgrastim | Injection 300 mcg |
| 503 | Hepatitis Immunoglobulin | Injection 1 ml |
| 504 | Hepatitis Immunoglobulin | Injection 0.5ml |
| 505 | Immune globulin IVIg | Injection 5% 50ml |
| 506 | Rho (D) immune globulin | Injection 300mcg |
| 507 | Salt free Albumin | Infusion 100 ml 20% |
| 508 | Salt free Albumin | Infusion 50 ml 20% |
| 509 | Snake Anti-Venom Sera | Injection 10 ml |
| 510 | Tetanus Immunoglobulin | Injection TT IG |
| 511 | Tetanus Toxoid | Injection 0.5ml |
| IV FLUIDS, ELECTROLYTES AND PARENTERAL NUTRITION | | |
| 512 | Amino Acids Solution | Infusion 8% 500 ml |
| 513 | Amino Acids Solution | Infusion 10% 500 ml |
| 514 | Calcium chloride + Glucose + Potassium Chloride + Sodium Acetate | Infusion 500 ml |
| 515 | Calcium Gluconate | Injection 10% 10 ml |
| 516 | Dextrose | Infusion 25% 1000 ml |
| 517 | Dextrose | Infusion 25% 20 ml |
| 518 | Dextrose | Infusion 25% 25ml |
| 519 | Dextrose | Infusion 5% 500 ml |
| 520 | Dextrose | Infusion 5% 1000 ml |
| 521 | Dextrose Saline | Infusion 5% + 0.9% 500 ml |
| 522 | Dextrose Water | Infusion 5% 100 ml |

| | | |
|---|--------------------------------------|-------------------------------------|
| 523 | Dextrose + Sodium Chloride | Infusion 5% + 0.45% 500 ml (1/2 DS) |
| 524 | Glycine solution | Infusion 3L |
| 525 | Lipid solution | Infusion 20% 250 ml |
| 526 | Magnesium Sulphate | Injection 500mg / 2 ml |
| 527 | Mannitol | Infusion 20% 500 ml |
| 528 | Oral Rehydration Salt | Sachet |
| 529 | Potassium Chloride | Infusion 25 ml |
| 530 | Potassium Chloride | Infusion 20 ml |
| 531 | Ringer lactate | Infusion 500 ml |
| 532 | Ringer lactate | Infusion 1000 ml |
| 533 | Ringer lactate + Dextrose | Infusion 500 ml |
| 534 | Ringer lactate + Dextrose | Infusion 1000 ml |
| 535 | Sodium Bicarbonate | Infusion 20ml |
| 536 | Sodium Bicarbonate | Infusion 25 ml |
| 537 | Sodium chloride | Infusion 0.9% 100 ml |
| 538 | Sodium chloride | Infusion 0.9%, 500 ml |
| 539 | Sodium chloride | Infusion 0.9%, 1000 ml |
| 540 | Sodium Chloride + Dextrose | Infusion 0.18% + 4.3%. 500 ml (1/5) |
| PSYCHOTROPIC AND ANTI CONVULSANT DRUGS | | |
| 541 | Alprazolam | Tablet 0.25 mg |
| 542 | Alprazolam | Tablet 0.5 mg |
| 543 | Carbamazepine | Tablet 200 mg |
| 544 | Carbamazepine | Tablet 400 mg |
| 545 | Carbamazepine | Syp 100mg |
| 546 | Clonazepam | Tablet 0.5 mg |
| 547 | Clonazepam | Tablet 2 mg |
| 548 | Clonazepam | Drops 0.25% |
| 549 | Diazepam | Injection 10mg |
| 550 | Diazepam | Tab 2mg |
| 551 | Diazepam | Tab 5mg |
| 552 | Diazepam | Tab 10mg |
| 553 | Diazepam | Solution 5mg |
| 554 | Divalproex Sodium / Valproate sodium | Injection 500 mg |
| 555 | Divalproex Sodium / Valproate sodium | Tablet 500 mg |
| 556 | Divalproex Sodium / Valproate sodium | Tablet 250 mg |

| | | |
|------------|--------------------------------------|----------------|
| 557 | Divalproex Sodium / Valproate sodium | Syp 250mg |
| 558 | Divalproex Sodium / Valproate sodium | Syp 500mg |
| 559 | Divalproex Sodium / Valproate sodium | Tablet 125 mg |
| 560 | Divalproex Sodium / Valproate sodium | Tab CR 500mg |
| 561 | Dothiepin | Tablet 25 mg |
| 562 | Dothiepin | Tablet 75 mg |
| 563 | Escitalopram | Tablet 5mg |
| 564 | Escitalopram | Tablet 10mg |
| 565 | Escitalopram | Tablet 20mg |
| 566 | Escitalopram | Drop 10mg |
| 567 | Fluoxetine HCl | Capsule 20 mg |
| 568 | Fluoxetine HCl | Tab 40mg |
| 569 | Haloperidol | Inj 5mg |
| 570 | Haloperidol | Tab 1.5mg |
| 571 | Haloperidol | Tab 10mg |
| 572 | Haloperidol | Tablet 5mg |
| 573 | Lamotrigine | Tab 25mg |
| 574 | Lamotrigine | Tab 50mg |
| 575 | Lamotrigine | Tab 100mg |
| 576 | Lamotrigine | Tab 200mg |
| 577 | Levetiracetam | Inj 500mg |
| 578 | Levetiracetam | Solution 100mg |
| 579 | Levetiracetam | Tab 250mg |
| 580 | Levetiracetam | Tab 500mg |
| 581 | Levetiracetam | Tab 750mg |
| 582 | Levetiracetam | Tab 1gm |
| 583 | Midazolam | Inj 1mg/ml |
| 584 | Midazolam | Tab 7.5mg |
| 585 | Midazolam | Tab 15mg |
| 586 | Olanzapine | Tablet 5 mg |
| 587 | Olanzapine | Tab 7.5mg |
| 588 | Olanzapine | Tab 10mg |
| 589 | Phenytoin | Inj 250mg |
| 590 | Phenytoin | Tab 100mg |
| 591 | Phenytoin | Susp 30mg |
| 592 | Phenytoin | Susp 125mg |

| | | |
|---------------------------------------|------------------------------|----------------------------|
| 593 | Pregabalin | Cap 25mg |
| 594 | Pregabalin | Cap 50mg |
| 595 | Pregabalin | Cap 75mg |
| 596 | Pregabalin | Cap 100mg |
| 597 | Pregabalin | Cap 150mg |
| 598 | Pregabalin | Cap 300mg |
| 599 | Procyclidine | Injection 10 mg |
| 600 | Procyclidine | Tablet 5 mg |
| 601 | Risperidone | Oral Soln 1mg |
| 602 | Risperidone | Tab 1mg |
| 603 | Risperidone | Tab 2mg |
| 604 | Risperidone | Tab 3mg |
| 605 | Risperidone | Tablet 4mg |
| 606 | Venlafaxine | Tab 75mg |
| 607 | Venlafaxine | Tab 150mg |
| 608 | Venlafaxine | Tab 50mg |
| 609 | Venlafaxine | Tab 37.50mg |
| 610 | Venlafaxine | Cap SR 75mg |
| RADIOLOGICAL DIAGNOSTIC AGENTS | | |
| 611 | Barium Sulfate | Liquid 60% |
| 612 | Barium Sulfate | Powder 99% W/W |
| 613 | Gadopentetate Dimeglumine | Infusion 10ml |
| 614 | Gadopentetate Dimeglumine | Infusion 20 ml |
| 615 | Iohexol | Infusion 300mg/ml 100ml |
| 616 | Iohexol | Infusion 300mg/ml 50ml |
| 617 | Iohexol | Infusion 370mg/ml 100ml |
| 618 | Iohexol | Infusion 370mg/ml 50ml |
| 619 | Iopromide | Infusion 300mg/ml 100ml |
| 620 | Iopromide | Infusion 300mg/ml 50ml |
| 621 | Iopromide | Infusion 370mg/ml 100ml |
| 622 | Iopromide | Infusion 370mg/ml 50ml |
| 623 | Sodium Diatrizoate/Meglumine | Infusion (All strengths) |
| 624 | Iobitridol | Solution 350 mg/ml (100ml) |
| 625 | Iobitridol | Solution 350 mg/ml (50ml) |
| 626 | Iobitridol | Solution 300 mg/ml (100ml) |
| 627 | Iobitridol | Solution 300 mg/ml (50ml) |

| RESPIRATORY DRUGS | | |
|--------------------------------------|---|---|
| 628 | Aminophylline | Injection 25mg/ml |
| 629 | Aminophylline | Tab 100mg |
| 630 | Aminophylline | Tab 200mg |
| 631 | Aminophylline | Tab 25mg |
| 632 | Acefyline | Syrup 125 mg/5ml |
| 633 | Aminophylline + Diphenhydramine + Ammonium Chloride | Syrup 32 mg + 8mg + 30 mg /5 ml 120 ml |
| 634 | Beclomethasone | Solution Neb 800mcg/2ml |
| 635 | Beclomethasone | Inhaler 250mcg |
| 636 | Budesonide + Formoterol Fumarate | Rota Caps 200/6 mcg |
| 637 | Budesonide + Formoterol Fumarate | Rota Caps 400/6 mcg |
| 638 | Budesonide + Formoterol Fumarate | Rota Caps 400/12 mcg |
| 639 | Ipratropium Bromide | Solution 250 mcg /ml |
| 640 | Ipratropium Bromide | Inhaler 20 mcg |
| 641 | Salbutamol | Solution 20 ml |
| 642 | Salbutamol | Syp 2mg/5ml |
| 643 | Salbutamol | Tab 2mg |
| 644 | Salbutamol | Tab 4mg |
| 645 | Salbutamol | Inj 0.5mg |
| 646 | Salmeterol + Fluticasone propionate | Inh 50/100mcg |
| 647 | Salmeterol + Fluticasone propionate | Inh 50/250mcg |
| 648 | Salmeterol + Fluticasone propionate | Inh 50/500mcg |
| 649 | Salmeterol + Fluticasone propionate | Inh 25/125mcg |
| 650 | Salmeterol + Fluticasone propionate | Inh 25/250mcg |
| 651 | Salmeterol + Fluticasone propionate | Inh 25/50mcg |
| DISINFECTANTS AND ANTISEPTICS | | |
| 652 | Chlorhexidine | 2% 1000ml |
| 653 | Chlorhexidine | 3% 1000ml |
| 654 | Chlorhexidine | 4% 1000ml |
| 655 | Chlorhexidine | Gel 7.1% |
| 656 | Hydrogen Peroxide | Solution 120 ml |
| 657 | Hydrogen Peroxide | Solution 60 ml |
| 658 | Povidone Iodine | Surgical Scrub 450 ml |
| 659 | Povidone Iodine | Solution 450 ml |
| TOPICAL PREPARATION | | |
| 660 | Fusidic Acid | Ointment 2% |

| | | |
|---|---|-------------------------------|
| 661 | Fusidic Acid | Cream 2% |
| 662 | Fusidic Acid | Tab 250mg |
| 663 | Miconazole | Oral Gel 2% |
| 664 | Miconazole | Vaginal cream with applicator |
| 665 | Miconazole | Topical Gel 2% |
| 666 | Miconazole | Topical Cream 2% |
| 667 | Polymyxin B Sulphate + Bacitracin zinc | Ointment 20 gm |
| 668 | Polymyxin B Sulphate + Bacitracin zinc | Eye Ointment 6 gm |
| 669 | Silver Sulfadiazine | Cream 1% |
| 670 | Dexamethasone / Moxifloxacin | Eye drops 0.1/0.5% |
| 671 | Artificial Tears (Dextran / Hypromellose) | Eye drops |
| ANTICANCER / ANTIRHEUMATIC DRUGS | | |
| 672 | Rituximab | Injection 500mg |
| 673 | Rituximab | Injection 100mg |
| 674 | Etanercept | Injection 50mg |
| 675 | Etanercept | injection 25mg |
| 676 | Eltrombopag | Tablets 50mg |
| 677 | Eltrombopag | Tablet 25mg |
| 678 | Mycophenolate Mofetil | Tablet 500 mg |
| 679 | Mycophenolate Sodium | Tablet 360mg |
| 680 | Ciclosporin | Cap 25mg |
| 681 | Ciclosporin | Cap 50mg |
| 682 | Ciclosporin | Capsule 100mg |
| 683 | Ciclosporin | Oral Soln 100mg |
| 684 | Secukinumab | Injection 150mg |
| 685 | Tocilizumab | injection 162/0.9ml |
| 686 | Tocilizumab | injection 80mg/4ml |
| 687 | Tocilizumab | Injection 20mg/ml |
| 688 | Tocilizumab | injection 400mg/20ml |
| 689 | Ocrelizumab | injection 300mg |
| 690 | Infliximab | Injection 100mg |
| 691 | Tofacitinib | Tablets 5mg |
| 692 | Tofacitinib | Tablets 10mg |
| 693 | Ranibizumab | injection 10mg |
| 694 | Norditropin | injection 5mg/1.5ml |
| 695 | Tacrolimus | Tablet 1mg |

| | | |
|--|------------------------------------|---------------------------------------|
| 696 | Tacrolimus | Tablet 0.5mg |
| 697 | Ruxolitinib | Tablet 10mg |
| 698 | Ruxolitinib | Tablet 15mg |
| 699 | Ruxolitinib | Tablet 20mg |
| 700 | Liraglutide | Prefilled Pen, injection 6mg/ml |
| 701 | Botulinum toxins | injection |
| 702 | Hydroxyurea | Tablets 500mg |
| 703 | Colchicine | Tab 0.5mg |
| MISCELLANEOUS DRUGS | | |
| 704 | Acetazolamide | Tablet 250mg |
| 705 | Albendazole | Tablet 200mg |
| 706 | Albendazole | Susp 100mg |
| 707 | Albendazole | Syrup 200mg/5ml |
| 708 | Alfacalcidol | Tablet 0.5 mcg |
| 709 | Alfacalcidol | Drops 2mcg/ml |
| 710 | Febuxastat | Tablet 80 mg |
| 711 | Febuxastat | Tablet 40 mg |
| 712 | Liquid Paraffin | Liquid |
| 713 | L-ornithine L-aspartate | Inj 5gm/10ml |
| 714 | L-ornithine L-aspartate | Syrup |
| 715 | Phenylephrine | Injection 10mg |
| 716 | Phenylephrine | Eye Drop 10% |
| 717 | Silver Nitrate | 5% Solution |
| 718 | Surfactant | Bovine Lipid Extract Inj 27mg/ml, 3ml |
| 719 | Surfactant | Proactant Alfa Inj 120mg/1.5ml |
| 720 | Tamsulosin | Cap 0.4mg |
| 721 | Zinc Oxide | Ointment 20% |
| MEDICAL DEVICES / SURGICAL DISPOSABLES/ NON-DRUG ITEMS (All Sizes- as applicable) | | |
| 722 | 3 way stop cork | Disposable |
| 723 | 3 way stop cork with extension | Disposable |
| 724 | Absorbable gelatin sponge | All Sizes |
| 725 | Adhesive Paper Tape | 1-inch * 4.5 m |
| 726 | Adhesive/Absorbent wound dressings | All Sizes |
| 727 | Arterial Line | 14 - 22 G |
| 728 | Blood Ketone Strips | .. |

| | | |
|------------|---|------------------------------|
| 729 | Blood sugar strips | .. |
| 730 | Bone Wax | .. |
| 731 | Catheter mount | .. |
| 732 | Cautery lead | Unipolar |
| 733 | Cautery lead | Bipolar |
| 734 | Chest Drainage Bottle/ under water seal | .. |
| 735 | Chest tube with/without trocar | All Sizes |
| 736 | Colostomy Bags | All Sizes |
| 737 | Cord Clamp | .. |
| 738 | Cotton Wool | 200gm |
| 739 | Cotton Wool | 100gm |
| 740 | Cotton Wool | Orthopedic grade |
| 741 | Crepe Bandage | 15 cm x 4.5 m |
| 742 | Crepe Bandage | 7.5 cm x 4.5 m |
| 743 | CVP Line | (Double Lumen) 4F |
| 744 | CVP Line | (Double Lumen) 5F |
| 745 | CVP Line | (Double Lumen) 7F |
| 746 | CVP Line | (Double Lumen) 8F |
| 747 | CVP Line | (Quad Lumen) 4Fr x 16cm |
| 748 | CVP Line | (Quad Lumen) 5Fr x 16cm |
| 749 | CVP Line | (Quad Lumen) 5.5Fr x 16cm |
| 750 | CVP Line | Quad Lumen 8.5Fr x 16cm |
| 751 | CVP Line | (Single Lumen) 14G |
| 752 | CVP Line | (Single Lumen) 16G |
| 753 | CVP Line | (Triple Lumen) 5.5Fr x 13cm |
| 754 | CVP Line | (Triple Lumen) 5.5Fr x 8cm |
| 755 | CVP Line | (Triple Lumen) 5F |
| 756 | CVP Line | (Triple Lumen) 7Fr x 15cm |
| 757 | CVP Line | (Triple Lumen) 7Fr x 20cm |
| 758 | CVP Line | (Triple Lumen) 7Fr x 25cm |
| 759 | CVP Line | (Triple Lumen) 7Fr x 30cm |
| 760 | Dial a flow | .. |
| 761 | Disposable Syringes | 1ml |
| 762 | Disposable Syringes | 1ml Insulin |
| 763 | Disposable Syringes | 5ml Auto disable syringe |
| 764 | Disposable Syringes | 3 ml Heparinized with needle |

| | | |
|------------|--|---|
| 765 | Disposable Syringes | 5 ml Heparinized with needle |
| 766 | Disposable Syringes | 10 ml |
| 767 | Disposable Syringes | 20 ml |
| 768 | Disposable Syringes | 50ml with needle |
| 769 | Disposable Syringes | 60ml with nozzle |
| 770 | Dressing Gauz Roll | 20m |
| 771 | Dressing Gauz Roll | 40m |
| 772 | Dressing Gauz pad | 10 x 10 cm |
| 773 | Dressing Gauz pad | 15 x 15 cm |
| 774 | Dressing Gauz pad (X-Ray detectable radiopaque) | 30 x 30 cm |
| 775 | HCV Kit | Sterilized |
| 776 | Hydrocolloid / alginate dressing | All Sizes |
| 777 | ECG Stickers | .. |
| 778 | EDTA Tube | .. |
| 779 | Endotracheal Tube with Cuff | All Sizes |
| 780 | Endotracheal Tube without Cuff | All Sizes |
| 781 | Epidural Kit | All sizes |
| 782 | Feeding Tubes / NG Tubes | All Sizes |
| 783 | Flatus Tube / Nelaton catheter | All Sizes |
| 784 | Foley's Catheter 2-Way Latex | All Sizes |
| 785 | Foley's Catheter 2-Way Silicon | All Sizes |
| 786 | Foley's Catheter 3-Way Latex | All Sizes |
| 787 | Foley's Catheter 3-Way Silicon | All Sizes |
| 788 | Gel Tube | .. |
| 789 | Gigli Saw | .. |
| 790 | HME Filter / Filter Bacterial HME | Adult |
| 791 | HME Filter / Filter Bacterial HME | Peads |
| 792 | IV Cannula with injection port and Heparin Stopper | 16 G, 18 G, 20G, 22G |
| 793 | IV Cannula with injection port and Heparin Stopper | 24G |
| 794 | IV Cannula with Injection port | 16 G, 18 G, 20G, 22G |
| 795 | IV Cannula with Injection port | 24G |
| 796 | Infusion Chamber | .. |
| 797 | IV Set | Sterile, minimum 150 cm length tubing, latex & Pyrogen Free |
| 798 | K-wires | 1.5mm |

| | | |
|------------|---------------------------------------|----------------------------|
| 799 | K-wires | 2 mm |
| 800 | K-wires | 2.5mm |
| 801 | K-wires | 3 mm |
| 802 | K-wires | Size 1, 1.5, 2.0, 2.5, 3.0 |
| 803 | Oropharyngeal airway | All Sizes |
| 804 | Latex examination gloves | Medium |
| 805 | Latex examination gloves | Large |
| 806 | Nitrile examination gloves | Medium |
| 807 | Nitrile examination gloves | Large |
| 808 | Mucus Extractor | .. |
| 809 | Nasal Cannula | Adult |
| 810 | Nasal Cannula | Peads |
| 811 | Nebulizer Kit | .. |
| 812 | Nebulizer Mask | Adult |
| 813 | Nebulizer Mask | Peads |
| 814 | Non Fabric Surgical Adhesive Fix Roll | All Sizes |
| 815 | Non Rebreathing mask | Adult |
| 816 | Non Rebreathing mask | Peads |
| 817 | Oxygen Mask | Adult |
| 818 | Oxygen Mask | Peads |
| 819 | Paraffin Tulle Dressing | All Sizes |
| 820 | Plaster of Paris Bandage POP Bandages | All Sizes |
| 821 | Disposable Plastic gloves | .. |
| 822 | Pressure Line | All Sizes |
| 823 | Prick Needle/ Lancet | .. |
| 824 | PT Tube | .. |
| 825 | Percutaneous Tracheostomy | All sizes |
| 826 | Redivac drain with perforated tube | .. |
| 827 | Spinal Needle | All Sizes |
| 828 | Suction Catheters | All Sizes |
| 829 | Suction tube with yuanker | 300cm |
| 830 | Surgical blade | All Sizes |
| 831 | Surgical Gloves (Powder) | 7, 7.5 ,8 |
| 832 | Surgical Gloves (Powder Free) | 7, 7.5 ,8 |
| 833 | Surgical Patties | .. |
| 834 | T-Piece (Oxygen recovery kit) | .. |
| 835 | Tracheostomy Tube | All Sizes |

| | | |
|--------------------------------|---------------------------|---|
| 836 | Transparent Film Dressing | Film Dressing |
| 837 | Urine Bag With Outlet | 2000ml with T-Valve |
| 838 | Zinc Oxide plaster | All sizes |
| <i>SURGICAL SUTURES</i> | | |
| 839 | Catgut Chromic | 20mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 4/0 |
| 840 | Catgut Chromic | 20mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 3/0 |
| 841 | Catgut Chromic | 26mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 2/0 |
| 842 | Catgut Chromic | 30mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 2/0 |
| 843 | Catgut Chromic | 30mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 0 |
| 844 | Catgut Chromic | 30mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 1 |
| 845 | Catgut Chromic | 40mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 2 |
| 846 | Catgut Chromic | 40mm, 1/2 circle round bodied taper point needle, strand length 75cm, USP size 0 |
| 847 | Catgut Chromic | 40mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 1 |
| 848 | Black Braided Silk | 16mm, ½ circle round bodied taper point, strand length 75cm 4/0 |
| 849 | Black Braided Silk | 16mm, 3/8 circle reverse cutting, strand length 75cm 4/0 |
| 850 | Black Braided Silk | 17mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 4/0 |
| 851 | Black Braided Silk | 30mm, ½ circle round bodied taper point, Strand length 75cm 3/0 |
| 852 | Black Braided Silk | 26mm, 3/8 circle conventional cutting needle, strand length 45 cm, USP size 3/0 |

| | | |
|------------|--------------------|---|
| 853 | Black Braided Silk | 16mm, 1/2 circle round bodied taper point needle, strand length 75 cm, USP size 3/0 |
| 854 | Black Braided Silk | 26mm, 3/8 circle reverse cutting, Strand length 75cm 2/0 |
| 855 | Black Braided Silk | 30mm, 3/8 circle reverse cutting needle, Strand length 75cm 2/0 |
| 856 | Black Braided Silk | 30mm, 3/8 circle reverse cutting, Strand length 75cm 0 |
| 857 | Black Braided Silk | 30mm, ½ circle round bodied, Strand length 75cm 0 |
| 858 | Black Braided Silk | 30mm, ½ circle round bodied, Strand length 75cm 1 |
| 859 | Black Braided Silk | 30mm, ½ circle round bodied taper point, Strand length 75cm 1 |
| 860 | Black Braided Silk | 30mm, 3/8 circle reverse cutting, Strand length 75cm 1 |
| 861 | Black Braided Silk | 40mm, ½ circle round bodied taper point needle, Strand length 75cm 1 |
| 862 | Black Braided Silk | 40mm, ½ circle round bodied taper point needle, strand length 75cm 2 |
| 863 | Polyglycolic Acid | 6mm, 3/8 micro point spatulated double armed needle 75cm 8/0. |
| 864 | Polyglycolic Acid | 6mm, 3/8 micro point spatulated double armed needle 75cm 6/0. |
| 865 | Polyglycolic Acid | 16mm, 3/8 circle reverse cutting, Strand length 75cm 4/0 |
| 866 | Polyglycolic Acid | 16mm, 3/8 circle reverse cutting, Strand length 75 cm 4/0 |
| 867 | Polyglycolic Acid | 17mm, ½ circle round bodied, Strand length 75cm 4/0 |
| 868 | Polyglycolic Acid | 16mm, 3/8 circle reverse cutting, Strand length 75 cm 3/0 |
| 869 | Polyglycolic Acid | 22mm, ½ circle round bodied taper point 75 cm 3/0 |
| 870 | Polyglycolic Acid | 26mm, ½ circle reverse cutting, Strand length 75 cm 2/0 |
| 871 | Polyglycolic Acid | 30mm, ½ circle round bodied taper point, strand length 75 cm 2/0 |
| 872 | Polyglycolic Acid | 48mm, ½ circle round bodied taper point, Strand length 90 cm 2 |

| | | |
|------------|-------------------|---|
| 873 | Polyglycolic Acid | 40mm, ½ circle round bodied taper point needle, strand length 90cm 2 |
| 874 | Polyglycolic Acid | 40mm, ½ circle round bodied taper point, strand length 75 cm 1 |
| 875 | Polyglycolic Acid | 30mm, ½ circle round bodied taper point, strand length 75 cm 0 |
| 876 | Polyglycolic Acid | 40mm, ½ circle round bodied taper point, strand length 90 cm 0 |
| 877 | Polyglycolic Acid | 40mm, ½ circle round bodied taper point, strand length 75 cm strand length 1 |
| 878 | Polypropylene | 13mm, 1/2 circle round bodied taper point double armed, strand length 75cm 6/0 |
| 879 | Polypropylene | 12mm 3/8 reverse cutting 6/0 45cm |
| 880 | Polypropylene | 16mm, 3/8 circle curved cutting, strand length 90cm 6/0 |
| 881 | Polypropylene | 13mm, 1/2 circle round bodied taper point double armed, strand length 75cm 5/0 |
| 882 | Polypropylene | 16mm, 1/2 circle round bodied taper point double armed, strand length 90cm 5/0 |
| 883 | Polypropylene | 16mm, 1/2 circle curved cutting, strand length 90cm 5/0 |
| 884 | Polypropylene | 15mm, 1/2 circle round bodied taper point needle, 75cm, 4/0 |
| 885 | Polypropylene | 16mm, 1/2 circle round bodied taper point double armed, strand length 90 cm 4/0 |
| 886 | Polypropylene | 19mm, 3/8 circle reverse cutting, strand length 75cm 4/0 |
| 887 | Polypropylene | 20mm, 1/2 circle curved cutting, strand length 90cm 3/0 |
| 888 | Polypropylene | 24mm, 3/8 circle reverse cutting, strand length 45cm 3/0 |
| 889 | Polypropylene | 25mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 3/0 |
| 890 | Polypropylene | 30 mm, 1/2 circle round bodied taper point double armed, strand length 90cm 3/0 |
| 891 | Polypropylene | 30mm, 1/2 circle round bodied taper point, strand length 75cm 2/0 |

| | | |
|------------|--------------------|---|
| 892 | Polypropylene | 75mm Straight curved cutting 75 cm, 2/0 |
| 893 | Polypropylene | 25mm, 1/2 circle round bodied taper point, strand length 90cm 2/0 |
| 894 | Polypropylene | 25mm 1/2 circle Round Body Taper cut point 75cm, 2/0 |
| 895 | Polypropylene | 30mm 1/2 Circle Round Body 75 cm, 0 |
| 896 | Polypropylene | 30mm 1/2 Circle Round Body 75 cm, 1 |
| 897 | Polypropylene | 40mm 1/2 Circle Round Body 75 cm, 0 |
| 898 | Polypropylene | 40mm 1/2 Circle Round Body 75 cm, 1 |
| 899 | Polypropylene Mesh | 6 x 11 cm |
| 900 | Polypropylene Mesh | 15 x 15 cm |
| 901 | Polypropylene Mesh | 30 x 30 cm |
| 902 | Polyester | All sizes |
| 903 | Nylon | 10-0 |

SECTION VII. SAMPLE FORMS

MANDATORY STANDARD FORMS

| | |
|--------------------|---|
| BID FORM 1: | BID COVER SHEET |
| BID FORM 2: | LETTER OF INTENTION BID |
| BID FORM 3: | AFFIDAVIT |
| BID FORM 4: | PRICE SCHEDULE FORMAT FOR FINANCIAL BID (To be submitted in separate sealed envelope) |
| BID FORM 5: | INTEGRITY PACT |
| BID FORM 6: | CONTRACT AGREEMENT |

BID FORM-1**BID COVER SHEET****Mandatory General Information of Applicant Firm**

NOTE: Complete filling of this form along with the provision of all requisite information is mandatory.

Missing or not providing any of the requisite information may lead to disqualification of the bidder/s from the bidding competition without any correspondence. Any appeal from bidder/s, for whatsoever reasons, shall not be entertained in such a case.

| S. No. | Name of the Bidding Firm: | |
|--------|--|--|
| 1. | Please indicate whether the firm is: Manufacturer of (A) Medical devices, suture, cotton and related items; or (B) Medicines; or Non-drug items, or Importer of (A) Medical devices, suture, cotton and related items; or (B) Medicines; or Non-drug items, or Both; Manufacturer as well as Importer of (A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items For various LRH-MTI formulary items offered for this bidding competition. | |
| 2. | Please indicate out of the following category/ices, under which the Firm is applying for bidding: Medical devices, suture, cotton and related items; Medicines; Non-drug items | |
| 3. | Please provide names, attested copies of CNICs, two recent attested photographs, valid street addresses in Pakistan, all working landline, mobile phone numbers and valid email address of the following: Owner/Proprietor of the Firm; and Managing Director / CEO of the Firm; and Focal person officially made responsible and authorized by the Firm for day-to-day official correspondence/communication with the procuring entity / purchasing entity related in relation to this bidding competition. <u>Note:</u> In case of winning this bidding competition the Focal person of the successful bidder shall be responsible for communication with procuring / purchasing entity/ices regarding supply related issues and his valid contact No. and address may be given in final approved rate list of Govt. LRH-MTI for facilitation of procuring / purchasing entity/ices. Please provide clear, legible and visible attested photocopies of all the valid requisite items mentioned items. | |

| | | |
|----|--|--|
| 4. | <p>Please provide the following valid information regarding applicant Firm:</p> <p>Complete street address of the:</p> <p>Head Office</p> <p>Main warehouse; and</p> <p>Valid & working official Landline Phone and Fax Numbers; and</p> <p>Valid Mobile phone number/s of the Focal Person registered which should be registered his/her CNIC No. and name; and</p> <p>Valid and functional Email address; and</p> <p>Official Website address/es.</p> | |
| 5. | <p>i. Please provide, in original, the bids security instrument amounting to Rupees 500,000/- along with the Financial Proposal in the sealed envelope in the form of valid Call Deposit Receipt (CDR) in the name of Hospital Director, Lady Reading Hospital, Khyber Pakhtunkhwa, Peshawar.</p> <p>Important Note: Please also provide an attested photocopy of the same bid's security document in the sealed envelope of technical Proposal.</p> | |
| 6. | <p>Please provide attested copies of the following Tax related valid documents:</p> <p>National Tax Number (NTN) of the Firm for Income Tax, and</p> <p>Last year Income Tax Return of the Firm; and</p> <p>Sale Tax Registration Certificate of the Firm; and</p> <p>Certificate of Professional Tax of the Firm.</p> <p>Should be on Active Tax payer list in FBR, Pakistan</p> | |
| 7. | <p>In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:</p> <p>Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and</p> <p>Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition</p> <p>Valid cGMP certificate issued by DRAP</p> <p>List of the quoted item/s</p> <p>In case of medical devices/NDI's, valid DRAP registration is mandatory</p> | |
| 8. | <p>In case of being Importers, the Firm should provide attested copies of the following documents also:</p> <p>Valid Drugs Sales License for the importer; and</p> <p>Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition, if required or where exemption is granted by law (DRAP) is to be verified and</p> <p>Valid Agency Agreement with the Foreign Principal Manufacturer entity/ices; and</p> <p>Valid cGMP/EC/Quality control/Quality assurance Certificate of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s) and List of the quoted items. (Non provision of this document shall lead to disqualification of the bidder);</p> <p>In case of examination glove & Adhesive Tape (Non-Sterilized) provision of E.C /Declaration of conformity from the principle Manufacturer duly attested from Embassy/high commission/consulate as the case may be of the country of origin can also be considered.</p> <p>In case of medical devices/NDI's, valid DRAP registration is mandatory.</p> | |

| | |
|----|--|
| 9. | <p>The bidding Firm shall also provide an Affidavit on Judicial Stamp Paper of the value of at least Rs. 100/- (Rs. One Hundred Only) for the following undertaking:</p> <p>I / We have carefully read the whole set of Standard Bidding Documents for this bidding competition and that I / We have fully understood and agree to all the provisions (including, but not limited to, those provided under ITB 29.1 of the Bid Data Sheet), terms and conditions, evaluation criteria, mechanism of evaluation & selection of items for which the Firm has applied for competition; and</p> <p>I / We fully understand and agree that the bidding competition for which I / We have applied to enter in, shall be based on merit-based scoring system for the evaluation of technical bids which has inverse relationship with the rates quoted by the bidders in their financial bids submitted; and that in this situation, the lowest financial bid/s may or may not win the bidding competition; and</p> <p>I / We guarantee that the quoted medical devices, surgical disposables and non-drug items are, and shall be, freely available in the market of Pakistan; and particularly in the market of Khyber Pakhtunkhwa Province; and</p> <p>I / We shall provide to the inspection team/s of expert/s authorized for the purpose by the Lady Reading Hospital (MTI) Khyber Pakhtunkhwa; an uninterrupted and free access to all relevant documents, sections of the manufacturing facilities / unit, storage and warehousing facilities as well as any other area relevant, as deemed appropriate by the above-mentioned team for their purpose of visit/s.</p> <p>In case any documents submitted in relation to this bidding competition or any undertaking given by the Firm, if found incorrect or false or misleading or diverting the decision making for the competition, shall be liable to be proceeded for blacklisting for any business with / by Lady Reading Hospital-Medical Teaching Institution, confiscation of bids security and / or any other lawful action as deemed appropriate by the Government of Khyber Pakhtunkhwa, including that to be taken in concert with the DRAP or any other body / entity of the Federal Government; and</p> <p>I / We have fully understood that the medical devices and items in the categories of cotton, bandages, adhesive tapes, etc. including other non-drug items shall be evaluated / examined by expert/s nominated by the competent authority of LRH-MTI at its sole discretion; and that the Firm shall fully agree and abide by the decision/opinion, whatsoever, of the said expert/s regarding the selection, or otherwise, of the quoted item/s for purchase / rate contracting.</p> <p>I / We also undertake that submission of any false/bogus/fake/forged/ fabricated/tampered document shall lead to disqualification of our firm from this bidding competition as well as to other lawful action/s to be taken by the concerned authorities.</p> <p>I / We have fully understood that no such documents shall be entertained by the Procuring entity / purchasing entity, which is issued after due date of Bid opening.</p> <p>That I have attached the requisite Bid security / CDR in the financial Bid.</p> |
| 10 | <p>I certify and affirm that I have attached /provided all the requisite mandatory documents / information including Bids Security with this Bid and that I fully understand that any document if not provided / missing shall result in the disqualification and declaring my bid as ineligible and thus non-responsive.</p> <p>Signatures: _____</p> <p>Name: _____</p> <p>CNIC No _____</p> <p>Designation _____</p> <p>Address _____</p> |

BID FORM 2

LETTER OF INTENTION

Bid Ref No.

Date of the Opening of Bids

Name of the Contract: {Add name, e.g., Supply of Dugs and Medicines, etc.}

To: [Name and address of procuring entity / purchasing entity]

Dear Sir/Madam

Having examined the bidding documents, including Addenda Nos. *[insert numbers & Date of individual Addendum]*, the receipt of which is hereby acknowledged, we, the undersigned, offer to supply and deliver the Goods under the above-named Contract in full conformity with the said bidding documents and at the rates/unit prices described in the financial bids are provided at the lowest minimum price in case of registered drugs/medicines and in case of non-drugs items (NDI), the prices are not more than the market rates.

We undertake, if our bid is accepted, to deliver the Goods in accordance with terms and condition of contract agreement.

We agree to abide by this bid, for the Bid Validity Period specified in the Bid Data Sheet and it shall remain binding upon us and may be accepted by you at any time before the expiration of that period.

Until the formal final Contract is prepared and executed between us, this bid, together with your written acceptance of the bid and your notification of award, shall constitute a binding Contract between us.

We understand that you are not bound to accept the lowest or any bid you may receive.

We undertake that, in competing for (and, if the award is made to us, in executing) the above contract, we will strictly observe the laws against fraud and corruption in force in Pakistan.

Dated this *[insert: number]* day of *[insert: month]*, *[insert: year]*.

Signed:

In the capacity of *[insert: title or position]*

Duly authorized to sign this bid for and on behalf of *[insert: name of Bidder]*

BID FORM-3

AFFIDAVIT (on Judicial Stamp Paper)

I/We, the undersigned [**Name of the Supplier**] hereby solemnly declare in Oath that and undertake that:

I / We, the undersigned, have read the contents of the Bidding Document and have fully understood it.

The Bid being submitted by the undersigned complies with the requirements enunciated in the bidding documents.

The Goods that I / We, the undersigned, propose to supply under this contract are eligible goods within the meaning of this SBD.

The undersigned are also eligible Bidders within the meaning of the Standard Bidding Documents.

The undersigned are solvent and competent to undertake the subject contract under the Laws of Pakistan.

The undersigned have not paid nor have agreed to pay, any Commissions or Gratuities to any official or agent related to this bid or award or contract.

The undersigned are not blacklisted or facing debarment from any Government, or its organization or project.

That undersigned has not employed any child labor in the organization/unit.

We understand that the Procuring entity / purchasing entity or any of its committees are not bound to accept the lowest or any other bid they may receive.

I / We affirm that the contents of this affidavit are correct to the best of my/our knowledge and belief.

Signatures with stamp Name:_____ Designation:_____ CNIC No._____
For Messrs. [***Name of Supplier***]

BID FORM-4**PRICE SCHEDULE FORMAT FOR FINANCIAL BID**

Note: *This form is to be submitted in a separate sealed envelope to be kept within the main sealed envelope of the bid.*

Price Schedule format for Financial Bid of LRH-MTI for the year 2024-2025

(A) Medical devices, suture, cotton and related items; **OR** (B) Medicines; **OR** (C) Non-drug items, the unit price of each item shall be quoted and submitted in the following format:

| S. No. | Serial No. of quoted item in the LRH-MTI list in SBD 2024-2025 | Generic Name with Trade Name of sizes/measurement's quoted item of quoted item | Rate Offered per unit in Pak. Rupees (Rs) |
|--------|--|--|---|
|--------|--|--|---|

BID FORM-5

INTEGRITY PACT (on Judicial Stamp Paper)

Declaration of Fees, Commission and Brokerage Etc. Payable by Suppliers of (A) Medical devices, suture, cotton and related items; (B) Medicines; (C) Non-drug items for Govt: LRH-MTI 2024-2025

In response to advertisement related to the bidding process / competition regarding purchase and supply of medical devices, non-drugs and surgical disposable items for 2024-2025 for the LRH-MTI, Mr. /Ms.

_____ s/o, d/o _____ bearing CNIC No. _____, and having the Designation of _____ in Messrs (M/S) [*Name of Supplier*] do hereby solemnly affirm, declare and certify on behalf of M/S [*Name of Supplier*] that:

[*Name of Supplier*] has not obtained or induced the procurement of any contract, right, interest, privilege or other obligation or benefit from LRH-MTI or any administrative subdivision or agency thereof or any other entity owned or controlled by LRH-MTI through any corrupt business practice; and

That without limiting the generality of the foregoing, [*Name of Supplier*] represents and warrants that it has fully declared the brokerage, commission, fees etc. paid or payable to anyone and not given or agreed to give and shall not give or agree to give to anyone within or outside Pakistan either directly or indirectly through any natural or juridical person, including its affiliate, agent, associate, broker, consultant, director, promoter, shareholder, sponsor or subsidiary, any commission, gratification, bribe, finder's fee or kickback, whether described as consultation fee or otherwise, with the object of obtaining or inducing the procurement of a contract, right, interest, privilege or other obligation or benefit in whatsoever form from LRH-MTI, except that which has been expressly declared pursuant hereto; and

That [*Name of Supplier*] has made and will make full disclosure of all agreements and arrangements with all persons in respect of or related to the transaction with LRH-MTI and has not taken any action or will not take any action to circumvent the above declaration, representation or warranty; and

That [*Name of Supplier*] accepts full responsibility and strict liability for making any false declaration, not making full disclosure, misrepresenting facts or taking any action likely to defeat the purpose of this declaration, representation and warranty. It agrees that any contract, right, interest, privilege or other obligation or benefit obtained or procured as aforesaid shall, without prejudice to any other rights and remedies available to LRH-MTI under any law, contract or other instrument, be voidable at the option of LRH-MTI; and

That notwithstanding any rights and remedies exercised by LRH-MTI in this regard, [*Name of Supplier*] agrees to indemnify LRH-MTI for any loss or damage incurred by it on account of its corrupt business practices and further pay compensation to LRH-MTI in an amount equivalent to ten times the sum of any commission, gratification, bribe, finder's fee or kickback given by [name of Supplier] as aforesaid for the purpose of obtaining or inducing the procurement of any contract, right, interest, privilege or other obligation or benefit in whatsoever form from LRH-MTI.

Signatures with stamp Name: _____ Designation: _____ CNIC No. _____
For Messrs. [*Name of Supplier*]

Witness No. 1

Witness No. 2

(Signatures, name, father's name, CNIC & address of each Witness)

WITNESS NO. 2

Signature: Name:

Father's Name: Address:

CNIC No.

BID FORM-6

CONTRACT AGREEMENT (on Judicial Stamp Paper)

THIS RATE CONTRACT AGREEMENT is made and agreed today on _____ day of _____, 2024 **in light of the provisions of BSDs for 2024-25** between the Hospital Director, LRH-MTI (*hereinafter referred to as the Procuring entity / purchasing entity or the first party, which expression shall, where the context admits, be deemed to include the assignee/s of the LRH-MTI*); and Messrs. [**Name of Supplier**] through Mr. _____ Designation _____ CNIC No. _____, (*hereinafter referred to as the Supplier or the second party or he/his, which expression, unless repugnant to the context, means and includes their legal heir/s, successors-in-interest, assignee/s and legal representative/s*) that:

WHEREAS the Procuring entity / purchasing entity has made a bidding competition for selection and rate contracting for medicines, medical devices, surgical disposables and other non-drug items (*hereinafter referred to as goods*) for actual purchases of the selected and rate contracted goods to be made by the offices / officers of the Lady Reading Hospital – Medical Teaching Institute, Peshawar, Khyber Pakhtunkhwa (*hereinafter called the Procuring / purchasing entity or Purchasing Agencies where the context so admits*); and

WHEREAS the Supplier declares that he is not a broker, middle-man, distributor or authorized dealer but himself a Manufacturer and / or direct Importer of goods for which he has won the bidding competition for supply of goods to the Procuring entity / purchasing entity throughout the province of Khyber Pakhtunkhwa (*hereinafter referred to as the Province*) to the Procuring / purchasing entity; and

WHEREAS both the parties have agreed that the Procuring / purchasing entity shall purchase all or some or none of the goods, as of details given in the Schedule-1 of this Contract Agreement, from the Supplier at the sole discretion of the individual Purchasing Agencies; and

WHEREAS the Supplier shall supply all the goods ordered by the Procuring / purchasing entity to the latter in the quantity as mentioned in the supply order to be issued by the Procuring / purchasing entity within the timeframe as mentioned in clause 18 of this contract agreement; Now, therefore, both the parties mutually agree to enter into this contract agreement as under:

1. The Supplier agrees to take full responsibility of the validity and implications, that may arise in future, of declaration submitted by him in the form of affidavit on judicial stamp paper along with the financial bids; and also that in case of any kind of breach of the said declaration, the Supplier shall be liable to be proceeded against by the Procuring entity / purchasing entity in accordance with the clauses of this rate contract agreement as well as relevant laws, rules and regulations of the Government of Khyber Pakhtunkhwa, as amended from time to time, to govern the situation/s.
2. The Supplier shall supply the ordered goods to the Procuring / purchasing entity exactly at the address of the official premises as given in the supply order issued to the former.
3. The Supplier shall be solely responsible for transportation, loading and / or unloading and staking of the supplied items till and at the time of delivery to the destination indicated by the Procuring / purchasing entity including any damage or untoward incidence, maintenance of required temperature and protection from light and other environmental conditions as well as other hazards that may

possibly or potentially affect the safety, quality and efficacy of the supplied items.

4. The Supplier shall **NOT** claim or charge transportation, loading / unloading, labor or any other charges related to or in the name of logistics, accidents, insurance, freight, etc.

5. All the goods supplied shall conform to the specifications approved by the Drug Regulatory Authority of Pakistan (*hereinafter referred to as the DRAP*).

6. The Purchasing Agency shall arrange to obtain randomized sample/s of each item of the supplied goods belonging to the categories of medicines, medical devices, surgical disposables and non-drug items through notified Drug Inspector/s concerned for sending the same to the concerned Drug Testing Laboratory for Test / Analysis as provided in the Drugs Act 1976, DRAP Act 2012 and rules frame thereunder, subject to the condition/s that:

- a.** the supplied medicines, medical devices, surgical disposables, etc. declared in contravention to any provision of the Drugs Act 1976, DRAP Act 2012 and rules framed there under, shall be replaced by the supplier at no cost to the Procuring / purchasing entity, and at the sole risk and cost of the supplier, within 07 days from the date of intimation to the supplier and / or his focal person as in the Bid Cover Sheet of the successful bid submitted by the supplier, at such place/s as the Procuring / purchasing entity may direct in accordance with clause-2 of this contract agreement. The Procuring / purchasing entity shall arrange to obtain sample/s of the replaced goods as in clause-6 above, for the purpose of Test / Analysis as provided in the Drugs Act 1976, DRAP Act 2012 and rules frame thereunder; and
- b.** in case of non-supply or delayed supply of replacement items as in clause 6 (a), the Supplier shall be liable for penalties as in clause No. 18 of this contract agreement; and
- c.** all the contravened stock of medicines, medical devices, surgical disposables and non-drug items, as in clause 6(a) above, shall be the case property under the Drugs Act, 1976, and
- d.** the supplier shall be responsible to make / provide arrangements for appropriate storage of seized stock at his sole risk, cost and responsibility, but under the legal supervision of concerned Drug Inspector; and
- e.** in case the destruction of the seized stock, as in clause 6 (a), (c) and (d) above, is required to be undertaken under the applicable laws and rules, all the costs involved in the execution of decision and destruction, whatsoever, shall be borne by the supplier; and
- f.** any of the item/s, as in clause-6 above, if initially declared to be in contravention with the provision/s of Drugs Act 1976, but later on declared as of standard quality by the concerned Appellate Drugs Testing Laboratory, shall be returned to the supplier by the concerned Drug Inspector in a lawful manner.

7. Supplier shall supply the freshly manufactured goods having maximum possible long expiry dates to the Procuring / purchasing entity. All the goods supplied shall conform to specifications mentioned in Schedule-I of this contract agreement, and to supply freshly manufactured goods to the Procuring / purchasing entity with the minimum remaining shelf life of at least 60%. In case, if the shelf life was less than 60%, then in case of no consumption, the goods shall be returned to the supplier for replacement at the risk and cost of supplier. The company will be bound to replace the short expiry items whereby intimation would be given to the manufacturer or importer or their designated focal person as the case may be. Intimation may be done six months before the expiry of the respective item (s).

8. In case of taking any action contravening to any provision/s of the applicable law/s and rules, the Supplier shall render himself liable to such lawful action/s as deemed appropriate and taken against him.

9. The items supplied shall be placed by the Supplier on their official websites indicating name of items, name of manufacturer / importer, Invoice No., Warranty & Date, Registration No, Batch No.,

Quantity, Price & Expiry date of the supplied goods and name of the Procuring / purchasing entity.

10. The Procuring / purchasing entity shall recommend to the Procuring entity / purchasing entity for taking legal / lawful action against the Supplier regarding non-supply, short supply, substituted supply, delayed supply or any other unlawful action / shortcoming, on the part of Supplier, pertaining to the Drugs Act 1976 and / or the execution of this contract agreement. The Procuring entity / purchasing entity shall take lawful / legal action against the Supplier in accordance with the clauses of this contract agreement as well as relevant laws, rules and regulations of the Government of Khyber Pakhtunkhwa, as amended from time to time, to govern suchlike situation/s, which may include, but not limited to, blacklisting, forfeiture of earnest money and performance guarantee, etc.

11. The Supplier agrees to the following conditions related to packing, packaging and labeling of the goods to be supplied to Purchasing Agencies under this contract agreement:

- a) Each item shall be supplied to Procuring / purchasing entity in the packing and packaging unit as approved and registered by the DRAP. The supplier shall supply all the unit items bearing the words **"PROPERTY OF LRH-MTI, NOT FOR SALE"** in block letters and clearly visible manner with indelible ink on the label, outer packing of each individual unit item as well as on its outer carton/s.
- b) The labels shall comply with all the requirements as laid down under the Drugs Labeling and Packing Rules 1986. The strip / blister shall clearly indicate expiry date of the same medicine in a clear and legible manner.
- c) The goods shall be packed and transported to the Procuring / purchasing entity in accordance with the provisions contained in the Standard Bidding Documents.
- d) The items related to the category of Absorbent Cotton / Surgical Gauze / Cotton Bandages / Crepe bandage, etc. shall be supplied in strict compliance with the instructions in this regard as circulated vide Notification No. F.6-6/2005-Reg-II (south) dated 13/9/2006 by the then Federal Ministry of Health, Pakistan.

12. The Procuring entity / purchasing entity or its representative shall have the right to inspect the manufacturing facility, premises, warehouse, godowns, laboratories etc. at any time during the financial year 2024-24 and/or till the execution of supply orders given under this contract agreement by Purchasing Agencies Khyber Pakhtunkhwa. If anything found in contravention of cGMP, clauses of Drug Act 1976 and/or this Contract Agreement the Procuring entity / purchasing entity shall have the sole liberty to take any lawful action as deem appropriate, against the supplier which may include but not limited to cancellation of supply order/ orders given to the suppliers by the Purchasing Agencies as well as imposition of penalties, forfeiture of supplied stock, forfeiture of performance guarantee and/or earnest money as the case may be, stoppage and/or recovery of payment made to the supplier.

13. RATE VALIDITY:

The Supplier agrees that the approved price of all individual items quoted in the financial bids shall remain valid till and up to 30th June 2025.

14. BID SECURITY:

As mentioned in Special Conditions of Contract, the bid security of 500,000/- from the supplier as already received by the Procuring entity / purchasing entity at the time of bids submission, shall be retained by the Procuring entity / purchasing entity as Performance Security till the end of contract period and will be released back to supplier after successful completion of all the contractual obligations of this contract agreement and approved Standard Bidding Documents.

15. WARRANTY:

- 1. For Drugs items the supplier shall provide warranty on prescribed form (2A), in accordance with the

Drugs Act, 1976, to the Procuring / purchasing entity for each item supplied in response to supply orders.

2. For Non-Drugs Items the supplier shall provide warranty to the Procuring / purchasing entity in accordance with Special Conditions of Contract as provided in the approved Standard Bidding Documents for this bidding competition, for each item supplied in response to supply orders.

16. PAYMENT SCHEDULE:

Bill for payment in triplicate along with all other relevant and required documents shall be submitted by the Supplier to the Procuring entity / purchasing entity immediately after complete supply of stock. The Supplier shall be bound to pay all sorts of government taxes, duties and stamp duties, imposed earlier or during the financial year by the Government of Pakistan or by the Provincial Government of Khyber Pakhtunkhwa on any supplied / purchased item.

17. FORCE MAJEURE:

a. In case of the situation related to Force Majeure, the Supplier may inform the Procuring entity / Purchasing entity and the Procuring / purchasing entity in writing about the situation immediately without delay along with solid proof through the fastest, lawful and available means of communication, but not through the electronic mail, and request the Procuring entity / purchasing entity for the grant of extension in the supply period.

b. The Procuring entity / purchasing entity, in case of being fully satisfied with the genuineness of situation arising from Force Majeure for the Supplier, may extend the period of supply of goods up to a maximum of not more than thirty days. However, the Procuring entity / purchasing entity and / or procuring / purchasing entity shall, in no case, be responsible or held responsible for any complications in making payments to Supplier by the Procuring / purchasing entity that may arise from the closure of financial year and lapse / surrender of public funds vis-à-vis the normal financial management procedures in public sector.

18. PENALTIES:

a. The supply of the ordered goods under this agreement shall be completed by the Supplier within thirty (30) days after the receipt of supply orders from the Procuring / purchasing entity, except in situation/s covered under clause 17 above. In case of delay in supplies reaching to the Procuring / purchasing entity, the following penalties shall be imposed by the Procuring / purchasing entity upon the Supplier:

i. Upon delay in supply from thirty-one to forty-five (31 to 45) days, a lump sum penalty amounting to three per cent (03%) of the total amount of the supply order for total number of items ordered in the same supply order issued to the Supplier, shall be levied through deducting the total amount of penalty from the total pre-tax payable billed amount by the Procuring / purchasing entity, irrespective of the number of items supplied late.

ii. Upon delay in supply from forty-six days up to sixty (46 to 60) days, in instead of three per cent (03%) as in clause 17(a)(i) above, a lump sum total penalty amounting to seven per cent (07%) of the total amount of the supply order for total number of items ordered in the same supply order issued to the Supplier, shall be levied through deducting the total amount of penalty from the total pre-tax payable billed amount by the Procuring / purchasing entity, irrespective of the number of items supplied late.

iii. After the expiry of the extended periods as in clause 17(a)(i)&(ii) above, the order shall stand cancelled to the extent of non-supplied items, and Procuring entity / purchasing entity shall have the right, duty and authority to impose any or all of the below mentioned penalties; that is

1. Immediately debarring the Supplier from future participation and business for next one to three (03) calendar/fiscal years with the Government of Khyber Pakhtunkhwa through LRH-MTI or any other health institution, project and / or Program directly or indirectly run or implemented by or through the provincial Health Department or autonomous Medical Teaching Institutions or district governments in Khyber Pakhtunkhwa; and / or

2. Forfeiting the earnest money and performance guarantee/CDR of the Supplier related to this contract agreement; and / or
 3. Initiating the process for and recommending for blacklisting of the Supplier with the Agencies as in clause 17(a)(iii)(1) above; and
 4. Proceeding for de-registration of item and / or the winning bidder by the DRAP as well as further judicial proceedings, if the situation so warrants in the opinion of Procuring entity / purchasing entity.
- b. The Supplier agrees to the effect that notwithstanding the provisions in this contract elsewhere and / or in the clause-18 (iii) (1) of this contract agreement and in addition to the provisions contained in and the implications arising thereof from any action taken under clause-18 (iii) (1), he/she shall be liable to be proceeded against under clause-18(a)(iii) also.
 - c. In case, if the firm failed to supply the goods within 60 days, the hospital will arrange the supply of requisite from alternate suppliers.

19. OBLIGATIONS AND OPTIONS IN CASE OF NON-FULFILMENT OF CONTRACTUAL OBLIGATIONS BY THE SUPPLIER.

Procuring entity may take any of the following actions if after the placement of the Purchase Order the supplier fails to deliver the goods within the prescribed period, according to the specifications, quantities and other terms and conditions given in the Purchase Order/Contract agreement: -

Purchase from any other source, at the risk and cost of the supplier, the goods not delivered or other goods of equivalent specifications, without canceling the Purchase Order/contract agreement; Cancel the Purchase Order/contract agreement at supplier's risk and cost. In such case, procuring entity reserves the right to take any action against supplier which it may deem fit under the circumstances including the blacklisting of the supplier; or recover any consequential losses/damages incurred by procuring entity by withholding any or all amounts otherwise due to the supplier against this or any other Purchase Order/Contract.

20. INDEMNITY:

- a. Notwithstanding any rights, duties and / or remedial measures and / or managerial actions taken and / or to be taken and / or any powers exercised and / or to be exercised by the Procuring entity / purchasing entity and / or Procuring / purchasing entity and / or Purchasing Officer/s with regard to the execution of this contract agreement, the Supplier agrees to indemnify them for any loss or damage incurred or inflicted upon by them in individual or official capacity upon the Supplier whether through any of their actions and / or practices and / or otherwise.
- b. The Supplier further agrees to pay compensation to the Lady Reading Hospital-Medical Teaching Institution of an amount equivalent to ten times the sum of any commission, gratification, bribe or kickback and / or finder's fee given by the Supplier for the purpose of obtaining and / or inducing the procurement of any contract, right, interest, privilege or other obligation/s or benefit in whatsoever form, from the Procuring entity / purchasing entity or any of the Purchasing Agencies.

21. RESOLUTION OF DISPUTES:

- a) The Procuring / purchasing entity and the Supplier shall make every effort to resolve amicably by direct negotiation any disagreement or dispute arising between them under or in connection with the contract / supplies.
- b) Despite such negotiation if the Procuring / purchasing entity & Supplier have been unable to resolve amicably a contract dispute, either party may refer the case to Chairman, Board of Governors for decision through a Dispute Resolution Committee under the chairmanship of Hospital Director LRH-MTI or any other person designated by him/her. The decision of the Dispute Resolution Committee shall be final and binding upon both the parties.

Signature:
Name:
Designation:
CNIC No.
Stamp:
For and on behalf of Manufacturers/Importer

Signature:
Hospital Director:
LRH-MTI Peshawar

WITNESS NO. 1

Signature:
Name:
Father's Name:
Address:
CNIC No.

WITNESS NO. 2

Signature:
Name:
Father's Name:
Address:
CNIC No.